

Pegylation

Clinical Pharmacokinetics

40, 539-551

DOI: 10.2165/00003088-200140070-00005

Citation Report

#	ARTICLE	IF	CITATIONS
1	Peginterferon- α -2a (40kD). <i>Drugs</i> , 2001, 61, 2263-2288.	4.9	92
2	Tumor Growth Inhibition by Interferon- β using PEGylated Protein or Adenovirus Gene Transfer with Constitutive or Regulated Expression. <i>Molecular Therapy</i> , 2002, 6, 50-56.	3.7	6
3	α 1-Antitrypsin: Not Just an Antiprotease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2002, 27, 652-654.	1.4	63
6	Fast forwarding pharmacogenomics. <i>Pharmacogenomics</i> , 2002, 3, 281-285.	0.6	0
7	Pegfilgrastim. <i>Hospital Pharmacy</i> , 2002, 37, 840-848.	0.4	0
8	Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. <i>Journal of Controlled Release</i> , 2002, 80, 259-271.	4.8	133
9	Use of peginterferon alfa-2a (40 KD) (Pegasys [®]) for the treatment of hepatitis C. <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 571-586.	6.6	221
10	Ligand Liposomes and Boron Neutron Capture Therapy. <i>Journal of Neuro-Oncology</i> , 2003, 62, 47-59.	1.4	5
11	Ligand liposomes and boron neutron capture therapy. <i>Journal of Neuro-Oncology</i> , 2003, 62, 47-59.	1.4	40
13	Rational design and engineering of therapeutic proteins. <i>Drug Discovery Today</i> , 2003, 8, 212-221.	3.2	180
14	Peptide and protein drug delivery to and into tumors: challenges and solutions. <i>Drug Discovery Today</i> , 2003, 8, 259-266.	3.2	332
15	Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. <i>Seminars in Oncology</i> , 2003, 30, 24-30.	0.8	58
16	Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. <i>Advanced Drug Delivery Reviews</i> , 2003, 55, 1261-1277.	6.6	860
17	Polyethylene glycol modified polyethylenimine for improved CNS gene transfer: effects of PEGylation extent. <i>Biomaterials</i> , 2003, 24, 2351-2362.	5.7	209
18	Targeted and sustained drug delivery using PEGylated galactosylated liposomes. <i>International Journal of Pharmaceutics</i> , 2003, 266, 77-84.	2.6	54
19	Repeated intrathecal administration of plasmid DNA complexed with polyethylene glycol-grafted polyethylenimine led to prolonged transgene expression in the spinal cord. <i>Gene Therapy</i> , 2003, 10, 1179-1188.	2.3	79
20	Improved biological and transcriptional activity of monopegylated interferon- β -2a isomers. <i>Pharmacogenomics Journal</i> , 2003, 3, 312-319.	0.9	16
21	Effect of pegylation on pharmaceuticals. <i>Nature Reviews Drug Discovery</i> , 2003, 2, 214-221.	21.5	2,920

#	ARTICLE	IF	CITATIONS
22	Pegylated interferons. <i>Clinics in Liver Disease</i> , 2003, 7, 139-148.	1.0	15
23	Tumour therapy with radionuclides: assessment of progress and problems. <i>Radiotherapy and Oncology</i> , 2003, 66, 107-117.	0.3	100
24	High-Pressure Transition of a Poly(ethylene glycol)-Grafted Phospholipid Monolayer at the Air/Water Interface. <i>Macromolecules</i> , 2003, 36, 7227-7235.	2.2	17
25	Immobilization of Quantum Dots in the Photo-Cross-Linked Poly(ethylene glycol)-Based Hydrogel. <i>Journal of Physical Chemistry B</i> , 2003, 107, 10464-10469.	1.2	48
26	Controlled Release of Proteins from Their Poly(Ethylene Glycol) Conjugates: A Drug Delivery Systems Employing 1,6-Elimination. <i>Bioconjugate Chemistry</i> , 2003, 14, 395-403.	1.8	78
27	Prospects for Antiviral Therapy. <i>Advances in Virus Research</i> , 2003, 61, 511-553.	0.9	16
28	Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon $\hat{1}\pm$ -2a (PEGASYS). <i>Protein Expression and Purification</i> , 2003, 30, 78-87.	0.6	155
29	Interferons, Interferon Inducers, and Interferon-Ribavirin in Treatment of Flavivirus-Induced Encephalitis in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 777-782.	1.4	55
30	Cell-Level Pharmacokinetic Model of Granulocyte Colony-Stimulating Factor: Implications for Ligand Lifetime and Potency in Vivo. <i>Molecular Pharmacology</i> , 2003, 63, 147-158.	1.0	39
31	New developments in the treatment of hepatitis C. <i>Gut</i> , 2003, 52, 756-757.	6.1	6
32	A Synthetic 15-mer Peptide (PCK3145) Derived from Prostate Secretory Protein Can Reduce Tumor Growth, Experimental Skeletal Metastases, and Malignancy-Associated Hypercalcemia. <i>Cancer Research</i> , 2004, 64, 5370-5377.	0.4	39
33	PEGylation of a Vesicular Stomatitis Virus G Pseudotyped Lentivirus Vector Prevents Inactivation in Serum. <i>Journal of Virology</i> , 2004, 78, 912-921.	1.5	143
34	Pegylated interferons. <i>Journal of Drug Evaluation</i> , 2004, 2, 113-127.	0.0	0
35	Strategies for targeting protein therapeutics to selected tissues and cells. <i>Expert Opinion on Biological Therapy</i> , 2004, 4, 65-73.	1.4	9
36	PEGylated dextran as long-circulating pharmaceutical carrier. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2004, 15, 621-630.	1.9	23
37	Pegylated interferon- $\hat{1}\pm$ 2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 37-44.	1.9	33
38	Minimizing the immunogenicity of protein therapeutics. <i>Drug Discovery Today</i> , 2004, 9, 82-90.	3.2	159
39	Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. <i>Advanced Drug Delivery Reviews</i> , 2004, 56, 1273-1289.	6.6	586

#	ARTICLE	IF	CITATIONS
40	MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 1081-9.	3.3	139
41	Recent peginterferon and ribavirin combination trials. <i>Current Hepatitis Reports</i> , 2004, 3, 30-37.	0.3	5
42	Polyethylene Glycol Modification of Filgrastim Results in Decreased Renal Clearance of the Protein in Rats. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 1367-1373.	1.6	79
43	Pharmacokinetic aspects of biotechnology products. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 2184-2204.	1.6	268
44	Population pharmacokinetic analysis of pegylated human erythropoietin in rats. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 3027-3038.	1.6	25
45	Preparative and analytical chromatography of pegylated myelopoietin using monolithic media. <i>Journal of Chromatography A</i> , 2004, 1041, 87-93.	1.8	21
46	Peginterferon- α 2a and Ribavirin Combination Therapy in Chronic Hepatitis C. <i>Annals of Internal Medicine</i> , 2004, 140, 346.	2.0	2,592
47	Photoacoustic Tomography of a Nanoshell Contrast Agent in the in Vivo Rat Brain. <i>Nano Letters</i> , 2004, 4, 1689-1692.	4.5	447
48	Pharmacokinetics of pegylated interferons: What is misleading?. <i>Digestive and Liver Disease</i> , 2004, 36, S334-S339.	0.4	44
49	Protein, peptide and non-peptide drug PEGylation for therapeutic application. <i>Expert Opinion on Therapeutic Patents</i> , 2004, 14, 859-894.	2.4	106
50	Biodegradable PEGylated Microspheres and Nanospheres. <i>American Journal of Drug Delivery</i> , 2004, 2, 157-171.	0.6	16
51	Pharmacodynamic evaluation of a PEGylated analogue of human growth hormone releasing factor in rats and pigs. <i>Growth Hormone and IGF Research</i> , 2004, 14, 226-234.	0.5	9
52	Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. <i>Cancer Letters</i> , 2004, 209, 171-176.	3.2	1,728
53	Second-generation biopharmaceuticals. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2004, 58, 185-196.	2.0	56
54	Oil-in-water lipid emulsions: implications for parenteral and ocular delivering systems. <i>Progress in Lipid Research</i> , 2004, 43, 489-533.	5.3	125
55	Peginterferon alfa-2a (40KD): A Potent Long-Acting Form of Interferon alfa-2a for the Treatment of Hepatitis C. , 2003, 519, 59-67.		5
56	Peginterferon alfa-2a: A review of approved and investigational uses. <i>Clinical Therapeutics</i> , 2004, 26, 991-1025.	1.1	63
57	RESUSCITATION FROM HEMORRHAGIC SHOCK WITH MalPEG-ALBUMIN: COMPARISON WITH MalPEG-HEMOGLOBIN. <i>Shock</i> , 2004, 22, 351-357.	1.0	24

#	ARTICLE	IF	CITATIONS
58	Development of Novel Drug Delivery System (DDS) Technologies for Proteomic-Based Drug Development. <i>Biological and Pharmaceutical Bulletin</i> , 2004, 27, 1483-1488.	0.6	8
59	Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer. <i>Anti-Cancer Drugs</i> , 2005, 16, 1045-1051.	0.7	12
60	Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40??kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12??kDa) plus ribavirin. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 899-904.	0.8	24
61	Functional polymers: from plastic electronics to polymer-assisted therapeutics. <i>Progress in Polymer Science</i> , 2005, 30, 844-857.	11.8	77
62	Emerging drugs for chronic hepatitis C. <i>Hepatology Research</i> , 2005, 32, 146-153.	1.8	12
63	Effect of lyophilization on the structure and phase changes of PEGylated-bovine serum albumin. <i>International Journal of Pharmaceutics</i> , 2005, 304, 124-134.	2.6	39
64	Gold Nanorod Bioconjugates. <i>Chemistry of Materials</i> , 2005, 17, 4636-4641.	3.2	411
65	Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin. <i>European Journal of Pharmaceutical Sciences</i> , 2005, 24, 465-475.	1.9	41
66	Utility of PEGylated recombinant adeno-associated viruses for gene transfer. <i>Journal of Controlled Release</i> , 2005, 108, 161-177.	4.8	68
67	The application of magnetic force differentiation for the measurement of the affinity of peptide libraries. <i>Journal of Magnetism and Magnetic Materials</i> , 2005, 293, 382-388.	1.0	14
68	Adsorption of poly(ethylene glycol)-modified ribonuclease A to a poly(lactide-co-glycolide) surface. <i>Biotechnology and Bioengineering</i> , 2005, 90, 856-868.	1.7	34
69	New Poly(oxyethylene) Derivatives from Diels-Alder Reactions of 3-[Methoxypoly(oxyethylene)]methylene Furan. <i>Macromolecular Chemistry and Physics</i> , 2005, 206, 1981-1987.	1.1	6
70	Effect of the covalent modification of horseradish peroxidase with poly(ethylene glycol) on the activity and stability upon encapsulation in polyester microspheres. <i>Journal of Pharmaceutical Sciences</i> , 2005, 94, 1808-1819.	1.6	26
71	CMC and regulatory considerations for polyethylene glycol-modified protein therapeutics. <i>Drug Delivery System</i> , 2005, 20, 620-634.	0.0	2
72	Immunogenicity and Rapid Blood Clearance of Liposomes Containing Polyethylene Glycol-Lipid Conjugates and Nucleic Acid. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 1020-1026.	1.3	176
73	Pegylated IFNs for chronic hepatitis C: an update. <i>Expert Opinion on Drug Delivery</i> , 2005, 2, 219-226.	2.4	21
74	Long-Circulating Polymeric Nanovectors for Tumor-Selective Gene Delivery. <i>Technology in Cancer Research and Treatment</i> , 2005, 4, 615-625.	0.8	116
75	Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects. <i>European Journal of Endocrinology</i> , 2005, 153, 249-256.	1.9	9

#	ARTICLE	IF	CITATIONS
76	Liposomes et formes pÃ©gylÃ©es : revue des mÃ©dicaments disponibles. Actualites Pharmaceutiques Hospitalieres, 2005, 1, 46-60.	0.1	0
77	Adsorption of Poly(ethylene glycol)-Modified Lysozyme to Silica. Langmuir, 2005, 21, 1328-1337.	1.6	54
78	Synthesis, Biological Activity, and Preliminary Pharmacokinetic Evaluation of Analogues of a Phosphosulfomannan Angiogenesis Inhibitor (PI-88). Journal of Medicinal Chemistry, 2005, 48, 8229-8236.	2.9	86
79	Bullous Sweet's syndrome in congenital neutropenia: Association with pegfilgrastim. Journal of the American Academy of Dermatology, 2005, 52, 901-905.	0.6	41
80	Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular carcinoma. Cancer Letters, 2005, 224, 67-80.	3.2	55
81	Applications of Liposomes in Ophthalmology. Survey of Ophthalmology, 2005, 50, 167-182.	1.7	156
82	PEGylation of Proteins as Tailored Chemistry for Optimized Bioconjugates. Advances in Polymer Science, 2005, , 95-134.	0.4	71
83	PEG-g-poly(GdDTPA-co-l-cystine):Ã Effect of PEG Chain Length on in Vivo Contrast Enhancement in MRI. Biomacromolecules, 2005, 6, 2305-2311.	2.6	45
84	Transport and functional behaviour of poly(ethylene glycol)-modified nanoporous alumina membranes. Nanotechnology, 2005, 16, 1335-1340.	1.3	31
85	PeginterferonÃ±2a (40 kDa) (PegasysÃ®) for hepatitis B. Expert Review of Anti-Infective Therapy, 2005, 3, 495-504.	2.0	11
86	Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein. Virology Journal, 2005, 2, 57.	1.4	71
87	Comparative Analysis of Polymer and Linker Chemistries on the Efficacy of Immunocamouflage of Murine Leukocytes. Artificial Cells, Blood Substitutes, and Biotechnology, 2006, 34, 305-322.	0.9	26
88	Physicochemical and Pharmacokinetic Characterization of Highly Potent Recombinant l-Methionine Ã³-Lyase Conjugated with Polyethylene Glycol as an Antitumor Agent. Cancer Research, 2006, 66, 2807-2814.	0.4	26
89	Nanomedicine. Clinical Pharmacokinetics, 2006, 45, 965-988.	1.6	150
90	Determining the Conformation of Thiolated Poly(ethylene glycol) on Au Nanoshells by Surface-Enhanced Raman Scattering Spectroscopic Assay. Analytical Chemistry, 2006, 78, 3277-3281.	3.2	91
91	Pharmacokinetic Consequences of Pegylation. Drug Delivery, 2006, 13, 399-409.	2.5	255
92	Peginterferon Ã±2b in the treatment of hepatitis C. Future Virology, 2006, 1, 279-292.	0.9	1
93	PeginterferonÃ±2ain the treatment of chronic hepatitis C. Future Virology, 2006, 1, 689-701.	0.9	0

#	ARTICLE	IF	CITATIONS
94	The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon α -2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1. <i>Journal of Viral Hepatitis</i> , 2006, 13, 552-559.	1.0	13
95	Post-translational modifications in the context of therapeutic proteins. <i>Nature Biotechnology</i> , 2006, 24, 1241-1252.	9.4	869
96	Synthesis and properties of new N-(2-hydroxypropyl)methacrylamide copolymers containing thiazolidine-2-thione reactive groups. <i>Reactive and Functional Polymers</i> , 2006, 66, 1525-1538.	2.0	124
97	Micellar Nanocarriers: Pharmaceutical Perspectives. <i>Pharmaceutical Research</i> , 2006, 24, 1-16.	1.7	1,586
98	Recombinant human alpha-1 proteinase inhibitor: towards therapeutic use. <i>Amino Acids</i> , 2006, 30, 317-332.	1.2	69
99	α _v β ₃ -integrin imaging: a new approach to characterise angiogenesis?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 54-63.	3.3	139
101	Drug transformation: Advances in drug delivery systems. <i>Canadian Journal of Anaesthesia</i> , 2006, 53, 1074-7.	0.7	10
102	GlycoPEGylation of recombinant therapeutic proteins produced in <i>Escherichia coli</i> . <i>Glycobiology</i> , 2006, 16, 833-843.	1.3	170
103	Developments towards effective treatments for Nipah and Hendra virus infection. <i>Expert Review of Anti-Infective Therapy</i> , 2006, 4, 43-55.	2.0	25
104	Computational Design of Peptides That Target Transmembrane Helices. <i>Science</i> , 2007, 315, 1817-1822.	6.0	271
105	Blocking LIF action in the uterus by using a PEGylated antagonist prevents implantation: A nonhormonal contraceptive strategy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 19357-19362.	3.3	89
106	microPET of Tumor Integrin α _v β ₃ Expression Using 18F-Labeled PEGylated Tetrameric RGD Peptide (18F-FPRGD4). <i>Journal of Nuclear Medicine</i> , 2007, 48, 1536-1544.	2.8	120
107	Pegylated interferon α -2a versus standard interferon α -2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. <i>Gut</i> , 2007, 57, 525-530.	6.1	69
108	Engineering Novel VPAC2-Selective Agonists with Improved Stability and Glucose-Lowering Activity in Vivo. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 320, 900-906.	1.3	26
109	Decreased circulation time offsets increased efficacy of PEGylated nanocarriers targeting folate receptors of glioma. <i>Nanotechnology</i> , 2007, 18, 385101.	1.3	91
110	Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes. <i>Journal of Endocrinology</i> , 2007, 192, 371-380.	1.2	46
111	PEGylation of cholecystokinin prolongs its anorectic effect in rats. <i>Peptides</i> , 2007, 28, 1003-1011.	1.2	17
112	Novel Delivery Systems for Interferons. <i>Critical Reviews in Biotechnology</i> , 2007, 27, 111-127.	5.1	9

#	ARTICLE	IF	CITATIONS
113	Long-circulating poly(ethylene glycol)-coated emulsions to target solid tumors. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2007, 67, 329-338.	2.0	34
114	Photoacoustic Tomography of a Rat Cerebral Cortex in vivo with Au Nanocages as an Optical Contrast Agent. <i>Nano Letters</i> , 2007, 7, 3798-3802.	4.5	404
116	CLINICAL IMPROVEMENT OF DIFFUSE LYMPHANGIOMATOSIS WITH PEGYLATED INTERFERON ALFA-2B THERAPY: Case Report and Review of the Literature. <i>Pediatric Hematology and Oncology</i> , 2007, 24, 513-524.	0.3	45
117	Delivery of Doxorubicin from Biodegradable PEG Hydrogels Having Schiff Base Linkages. <i>Journal of Bioactive and Compatible Polymers</i> , 2007, 22, 589-601.	0.8	86
118	Guideline on prevention and treatment of chronic hepatitis B in China (2005). <i>Chinese Medical Journal</i> , 2007, 120, 2159-2173.	0.9	89
119	Bivalent Peptides as Models for Multimeric Targets of PDZ Domains. <i>ChemBioChem</i> , 2007, 8, 443-452.	1.3	19
120	Microparticles and nanoparticles for drug delivery. <i>Biotechnology and Bioengineering</i> , 2007, 96, 203-209.	1.7	430
121	High-yields and extended serum half-life of human interferon β expressed in tobacco cells as arabinogalactan-protein fusions. <i>Biotechnology and Bioengineering</i> , 2007, 97, 997-1008.	1.7	93
122	Nanotechnology platforms and physiological challenges for cancer therapeutics. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2007, 3, 103-110.	1.7	169
123	PEGylated cholecystokinin prolongs satiation in rats: dose dependency and receptor involvement. <i>British Journal of Pharmacology</i> , 2007, 152, 396-403.	2.7	14
124	Pharmacodynamics of peginterferon alfa-2a and peginterferon alfa-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 369-376.	1.9	37
125	Solid-Phase PEGylation of Recombinant Interferon β for Site-Specific Modification: Process Performance, Characterization, and <i>In Vitro</i> Bioactivity. <i>Bioconjugate Chemistry</i> , 2007, 18, 1728-1734.	1.8	69
126	Determination of Binding Constants of Polyethylene Glycol Vancomycin Derivatives to Peptide Ligands Using Affinity Capillary Electrophoresis. <i>Chromatographia</i> , 2007, 65, 299-303.	0.7	5
127	Modulation of protein biophysical properties by chemical glycosylation: biochemical insights and biomedical implications. <i>Cellular and Molecular Life Sciences</i> , 2007, 64, 2133-2152.	2.4	108
128	Peritoneal Macrophage Uptake, Pharmacokinetics and Biodistribution of Macrophage-Targeted PEG-fMLF (N-Formyl-Methionyl-Leucyl-Phenylalanine) Nanocarriers for Improving HIV Drug Delivery. <i>Pharmaceutical Research</i> , 2007, 24, 2110-2119.	1.7	39
129	Imaging of integrin $\alpha_3\beta_1$ expression. <i>Cancer and Metastasis Reviews</i> , 2008, 27, 631-644.	2.7	208
130	Contrast-Enhanced MRI-Guided Photodynamic Cancer Therapy with a Pegylated Bifunctional Polymer Conjugate. <i>Pharmaceutical Research</i> , 2008, 25, 2002-2011.	1.7	52
131	Rational identification of a novel peptide for targeting nanocarriers to 9L glioma. <i>Journal of Biomedical Materials Research - Part A</i> , 2008, 87A, 728-738.	2.1	7

#	ARTICLE	IF	CITATIONS
132	An New Avenue to Nonfouling Materials. <i>Advanced Materials</i> , 2008, 20, 335-338.	11.1	369
133	Site-directed PEGylation as successful approach to improve the enzyme replacement in the case of prolidase. <i>International Journal of Pharmaceutics</i> , 2008, 358, 230-237.	2.6	22
134	Therapeutic Nanoparticles for Drug Delivery in Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 1310-1316.	3.2	2,565
135	Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. <i>Advanced Drug Delivery Reviews</i> , 2008, 60, 13-28.	6.6	225
136	Activity and regulation of glycoPEGylated factor VIIa analogs. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1525-33.	1.9	13
137	DARPinS: A new generation of protein therapeutics. <i>Drug Discovery Today</i> , 2008, 13, 695-701.	3.2	208
138	Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: Optimization by PEG size selection. <i>Journal of Controlled Release</i> , 2008, 125, 68-75.	4.8	71
139	Lipidization of human interferon-alpha: A new approach toward improving the delivery of protein drugs. <i>Journal of Controlled Release</i> , 2008, 129, 11-17.	4.8	24
140	The Impact of Molecular Weight and PEG Chain Length on the Systemic Pharmacokinetics of PEGylated Poly-L-Lysine Dendrimers. <i>Molecular Pharmaceutics</i> , 2008, 5, 449-463.	2.3	165
141	Designing PEGylated therapeutic molecules: advantages in ADMET properties. <i>Expert Opinion on Drug Discovery</i> , 2008, 3, 1293-1307.	2.5	30
142	Disposition of Drugs in Block Copolymer Micelle Delivery Systems. <i>Clinical Pharmacokinetics</i> , 2008, 47, 619-634.	1.6	72
143	Early and Sustained Virological Response in Non-Responders with Chronic Hepatitis C. <i>Drugs</i> , 2008, 68, 791-801.	4.9	18
144	Tailoring plasmonic substrates for surface enhanced spectroscopies. <i>Chemical Society Reviews</i> , 2008, 37, 898.	18.7	522
145	Factors that contribute to the immunogenicity of therapeutic recombinant human proteins. <i>Thrombosis and Haemostasis</i> , 2008, 99, 874-882.	1.8	52
146	Peg-Interferon Alpha-2a versus Peg-Interferon Alpha-2b in Nonresponders with HCV Active Chronic Hepatitis: A Pilot Study. <i>Journal of Interferon and Cytokine Research</i> , 2008, 28, 623-630.	0.5	27
147	Novel Controlled-Release Lemna-Derived IFN- α 2b (Locteron): Pharmacokinetics, Pharmacodynamics, and Tolerability in a Phase I Clinical Trial. <i>Journal of Interferon and Cytokine Research</i> , 2008, 28, 113-122.	0.5	74
148	Liposomal vasoactive intestinal peptide for lung application: Protection from proteolytic degradation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 70, 153-164.	2.0	39
149	Synthetic polymeric vectors in gene therapy. <i>Current Opinion in Solid State and Materials Science</i> , 2008, 12, 89-102.	5.6	45

#	ARTICLE	IF	CITATIONS
150	Optimal Design and Characterization of Superparamagnetic Iron Oxide Nanoparticles Coated with Polyvinyl Alcohol for Targeted Delivery and Imaging. <i>Journal of Physical Chemistry B</i> , 2008, 112, 14470-14481.	1.2	232
152	The role of pegvisomant in the treatment of acromegaly. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 691-704.	1.4	9
153	Iron Tris(bipyridine)-Centered Poly(ethylene glycol)-Poly(lactic acid) Star Block Copolymers. <i>Macromolecules</i> , 2008, 41, 9397-9405.	2.2	24
154	Optimizing Size and Copy Number For PEG-fMLF (N-Formyl-methionyl-leucyl-phenylalanine) Nanocarrier Uptake by Macrophages. <i>Bioconjugate Chemistry</i> , 2008, 19, 28-38.	1.8	31
155	Single-Site Cys-Substituting Mutation of Human Lectin Galectin-2: Modulating Solubility in Recombinant Production, Reducing Long-Term Aggregation, and Enabling Site-Specific MonoPEGylation. <i>Biomacromolecules</i> , 2008, 9, 3223-3230.	2.6	19
156	Mixing Behavior of a Poly(ethylene glycol)-Grafted Phospholipid in Monolayers at the Air/Water Interface. <i>Langmuir</i> , 2008, 24, 13019-13029.	1.6	5
157	Auditing Protein Therapeutics Management by Professional APCs: Toward Prevention of Immune Responses against Therapeutic Proteins. <i>Journal of Immunology</i> , 2008, 181, 1609-1615.	0.4	18
158	Pegylated Interferons: Clinical Applications in the Management of Hepatitis C Infection. , 2008, , 237-296.		0
159	Evasion of Ribonuclease Inhibitor as a Determinant of Ribonuclease Cytotoxicity. <i>Current Pharmaceutical Biotechnology</i> , 2008, 9, 185-199.	0.9	93
160	Pharmacotherapy of chronic hepatitis C virus infection â€” the IDEAL trial: â€”2b or not 2b (= 2a), that is the questionâ€™. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2845-2857.	0.9	6
162	Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice. <i>Acta Pharmaceutica</i> , 2009, 59, 133-144.	0.9	65
163	In situ growth of a stoichiometric PEG-like conjugate at a protein's N-terminus with significantly improved pharmacokinetics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 15231-15236.	3.3	159
164	Quantitative determination of pegylated consensus interferon in rhesus monkey serum using a competitive enzyme-linked immunosorbent assay. <i>Immunopharmacology and Immunotoxicology</i> , 2009, 31, 543-549.	1.1	9
165	Pegvisomant: current and potential novel therapeutic applications. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 1553-1563.	1.4	8
166	HBV and HCV Therapy. <i>Viruses</i> , 2009, 1, 484-509.	1.5	7
167	Understanding Membrane Proteins. How to Design Inhibitors of Transmembrane Proteinâ€™Protein Interactions. <i>Nucleic Acids and Molecular Biology</i> , 2009, , 315-337.	0.2	1
168	PEGylation of interleukinâ€™10 for the mitigation of enhanced pain states. <i>Journal of Biomedical Materials Research - Part A</i> , 2010, 93A, 1169-1179.	2.1	29
169	Recent Advances in Affinity Capillary Electrophoresis (2007). <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 394-410.	1.6	47

#	ARTICLE	IF	CITATIONS
170	Synthesis, Characterization and In Vivo Activity of Salmon Calcitonin Coconjugated With Lipid and Polyethylene Glycol. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 1438-1451.	1.6	11
171	Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 1556-1567.	1.6	32
172	Interleukin-2: Evaluation of Routes of Administration and Current Delivery Systems in Cancer Therapy. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 2268-2298.	1.6	43
174	Design and Synthesis of Highly Potent and Plasma-Stable Dimeric Inhibitors of the PSD-95-NMDA Receptor Interaction. <i>Angewandte Chemie - International Edition</i> , 2009, 48, 9685-9689.	7.2	55
175	Nanoparticles in cellular drug delivery. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 2950-2962.	1.4	744
176	Nanoparticulate Systems for Growth Factor Delivery. <i>Pharmaceutical Research</i> , 2009, 26, 1561-1580.	1.7	157
177	Lipid-based emulsion system as non-viral gene carriers. <i>Archives of Pharmacal Research</i> , 2009, 32, 639-646.	2.7	35
178	Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC). <i>Cancer Cell International</i> , 2009, 9, 9.	1.8	65
179	Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab. <i>Dermatologic Therapy</i> , 2009, 22, S16-S18.	0.8	21
180	Interferon alpha delivery systems for the treatment of hepatitis C. <i>International Journal of Pharmaceutics</i> , 2009, 369, 121-135.	2.6	26
181	Formulation of multifunctional oil-in-water nanosized emulsions for active and passive targeting of drugs to otherwise inaccessible internal organs of the human body. <i>International Journal of Pharmaceutics</i> , 2009, 381, 62-76.	2.6	48
182	Effect of the oligo(ethylene glycol) group on the antioxidant activity of manganese salen complexes. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 614-617.	1.0	22
183	Separation of PEGylated from unmodified ribonuclease A using sepharose media. <i>Separation and Purification Technology</i> , 2009, 65, 105-109.	3.9	35
184	Supramolecular aggregates containing lipophilic Gd(III) complexes as contrast agents in MRI. <i>Coordination Chemistry Reviews</i> , 2009, 253, 2193-2213.	9.5	124
185	Absorption of 10-hydroxycamptothecin into the coat of magnetoliposomes. <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 2009, 343, 20-23.	2.3	4
186	Correlations between in vitro potency of polyethylene glycol-protein conjugates and their chromatographic behavior. <i>Analytical Biochemistry</i> , 2009, 389, 27-31.	1.1	21
187	Poly(ethylene glycol)-Modified Proteins: Implications for Poly(lactide-co-glycolide)-Based Microsphere Delivery. <i>AAPS Journal</i> , 2009, 11, 88-98.	2.2	45
188	Synthesis of Linear Polyether Polyol Derivatives As New Materials for Bioconjugation. <i>Bioconjugate Chemistry</i> , 2009, 20, 780-789.	1.8	55

#	ARTICLE	IF	CITATIONS
189	T cell epitope: Friend or Foe? Immunogenicity of biologics in context†. <i>Advanced Drug Delivery Reviews</i> , 2009, 61, 965-976.	6.6	90
190	Engineered Nanomaterial Transformation under Oxidative Environmental Conditions: Development of an <i>in vitro</i> Biomimetic Assay. <i>Environmental Science & Technology</i> , 2009, 43, 1598-1604.	4.6	54
191	Intracellular Trafficking and Subcellular Distribution of a Large Array of HPMA Copolymers. <i>Biomacromolecules</i> , 2009, 10, 1704-1714.	2.6	36
192	⁶⁸ Ga-Labeling of Biotin Analogues and their Characterization. <i>Bioconjugate Chemistry</i> , 2009, 20, 1146-1151.	1.8	28
193	Iron Tris(bipyridine) PEG Hydrogels with Covalent and Metal Coordinate Cross-Links. <i>Biomacromolecules</i> , 2009, 10, 128-133.	2.6	21
194	Gastrointestinal biodurability of engineered nanoparticles: Development of an <i>in vitro</i> assay. <i>Nanotoxicology</i> , 2009, 3, 202-214.	1.6	45
195	Lack of tolerance development with long-term administration of PEGylated cholecystokinin. <i>Peptides</i> , 2009, 30, 699-704.	1.2	8
196	Superparamagnetic Iron Oxide Nanoparticles with Rigid Cross-linked Polyethylene Glycol Fumarate Coating for Application in Imaging and Drug Delivery. <i>Journal of Physical Chemistry C</i> , 2009, 113, 8124-8131.	1.5	164
197	Multiphysics Flow Modeling and <i>in Vitro</i> Toxicity of Iron Oxide Nanoparticles Coated with Poly(vinyl Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.5	91
198	Pharmacokinetics of erythropoiesis-stimulating agents. , 2009, , 199-223.		1
199	Peginterferon- α 2a (40%kD). <i>Drugs</i> , 2009, 69, 2633-2660.	4.9	17
200	Molecular Dynamics Study of the Structure and Interparticle Interactions of Polyethylene Glycol-Conjugated PAMAM Dendrimers. <i>Journal of Physical Chemistry B</i> , 2009, 113, 13202-13207.	1.2	60
201	PEGylated α interferons: two different strategies to achieve increased efficacy. , 2009, , 205-216.		1
202	Pegylated IFN- α 2a and ribavirin in the treatment of hepatitis C. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 925-935.	2.0	19
204	PET Imaging of Angiogenesis. <i>PET Clinics</i> , 2009, 4, 17-38.	1.5	49
205	Importance of Biopolymer Molecular Flexibility in Ultrafiltration Processes. <i>Industrial & Engineering Chemistry Research</i> , 2009, 48, 2395-2403.	1.8	11
206	Modeling HCV kinetics under therapy using PK and PD information. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 321-332.	1.5	32
207	The interferons: Past, present and future. <i>Digestive and Liver Disease Supplements</i> , 2009, 3, 3-8.	0.2	1

#	ARTICLE	IF	CITATIONS
208	A Coarse-Grained Model for Polyethylene Oxide and Polyethylene Glycol: Conformation and Hydrodynamics. <i>Journal of Physical Chemistry B</i> , 2009, 113, 13186-13194.	1.2	338
211	Synthesis and Characterization of Methotrexate Polyethylene Glycol Esters as a Drug Delivery System. <i>Chemical and Pharmaceutical Bulletin</i> , 2010, 58, 147-153.	0.6	30
212	Design, synthesis, characterization and in-vivo activity of a novel salmon calcitonin conjugate containing a novel PEG-lipid moiety. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 62, 296-304.	1.2	6
213	Target-specific delivery of peptide-based probes for PET imaging. <i>Advanced Drug Delivery Reviews</i> , 2010, 62, 1005-1022.	6.6	161
214	Polymer-protein conjugates: an enzymatic activity perspective. <i>Polymer Chemistry</i> , 2010, 1, 1352.	1.9	153
215	PEG-based Polyplex Design for Gene and Nucleotide Delivery. <i>Israel Journal of Chemistry</i> , 2010, 50, 175-184.	1.0	14
216	Positron emission tomography tracers for imaging angiogenesis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 86-103.	3.3	102
217	Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. <i>Biomaterials</i> , 2010, 31, 6574-6581.	5.7	461
218	Smart nanomaterials for cancer therapy. <i>Science China Chemistry</i> , 2010, 53, 2241-2249.	4.2	17
219	¹⁸ F-Labeled Galacto and PEGylated RGD Dimers for PET Imaging of $\alpha v \beta 3$ Integrin Expression. <i>Molecular Imaging and Biology</i> , 2010, 12, 530-538.	1.3	131
220	CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes. <i>Journal of Controlled Release</i> , 2010, 142, 160-166.	4.8	71
221	Poly(ethylene glycol) modification enhances penetration of fibroblast growth factor 2 to injured spinal cord tissue from an intrathecal delivery system. <i>Journal of Controlled Release</i> , 2010, 144, 25-31.	4.8	50
222	Long-term stability of sterically stabilized liposomes by freezing and freeze-drying: Effects of cryoprotectants on structure. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 41, 546-555.	1.9	173
223	Radiofluorinated Pyrimidine-2,4,6-triones as Molecular Probes for Noninvasive MMP-Targeted Imaging. <i>ChemMedChem</i> , 2010, 5, 777-789.	1.6	59
224	Metabolic limitations of the use of nucleoside analogs in cancer therapy may be overcome by application of nanoparticles as drug carriers: A review. <i>Drug Development Research</i> , 2010, 71, 383-394.	1.4	6
225	MALDI linear TOF mass spectrometry of PEGylated (glyco)proteins. <i>Journal of Mass Spectrometry</i> , 2010, 45, 612-617.	0.7	24
226	Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon- $\alpha 2b$ -ribavirin combination therapy. <i>Journal of Medical Virology</i> , 2010, 82, 1640-1646.	2.5	5
227	Delivery of Therapeutic Proteins. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 2557-2575.	1.6	454

#	ARTICLE	IF	CITATIONS
228	New Amphiphilic Conjugates of Mono- and Bis(carboxy)-PEG _{2,000} Polymers with Lipoamino Acids as Surface Modifiers of Colloidal Drug Carriers. <i>Macromolecular Chemistry and Physics</i> , 2010, 211, 1148-1156.	1.1	13
229	Engineering the properties of metal nanostructures via galvanic replacement reactions. <i>Materials Science and Engineering Reports</i> , 2010, 70, 44-62.	14.8	189
230	Dual affinity method for plasmid DNA purification in aqueous two-phase systems. <i>Journal of Chromatography A</i> , 2010, 1217, 1429-1436.	1.8	22
231	Near infrared imaging with nanoparticles. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2010, 2, 461-477.	3.3	143
232	Delivery of DNA vaccines: an overview on the use of biodegradable polymeric and magnetic nanoparticles. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2010, 2, 205-218.	3.3	67
233	Effect of glycoPEGylation on factor VIIa binding and internalization. <i>Haemophilia</i> , 2010, 16, 339-348.	1.0	29
234	A perspective on modelling hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2010, 17, 825-833.	1.0	76
235	Multiple doses of pegylated long-acting growth hormone are well tolerated in healthy male volunteers and possess a potential once-a-weekly treatment profile. <i>Clinical Endocrinology</i> , 2010, 73, 769-776.	1.2	14
236	Safety, Tolerability, and Immunogenicity of Interferons. <i>Pharmaceuticals</i> , 2010, 3, 1162-1186.	1.7	24
237	Deciphering the Kinetic Binding Mechanism of Dimeric Ligands Using a Potent Plasma-stable Dimeric Inhibitor of Postsynaptic Density Protein-95 as an Example. <i>Journal of Biological Chemistry</i> , 2010, 285, 28252-28260.	1.6	29
238	In situ growth of a PEG-like polymer from the C-terminus of an intein fusion protein improves pharmacokinetics and tumor accumulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 16432-16437.	3.3	143
239	Efficacy and Tolerability of Pegylated Interferon- α 2a plus Ribavirin versus Pegylated Interferon- α 2b plus Ribavirin in Treatment-Naïve Chronic Hepatitis C Patients. <i>Antivirology</i> , 2010, 53, 146-153.	1.2	18
241	Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; a case of FVIII, FVIIa and G-CSF. <i>Expert Opinion on Drug Delivery</i> , 2010, 7, 187-201.	2.4	13
242	Batch purification of high-purity lysozyme from egg white and characterization of the enzyme modified by PEGylation. <i>Pharmaceutical Biology</i> , 2010, 48, 554-562.	1.3	13
243	Sustained Exogenous Expression of Therapeutic Levels of IFN- γ Ameliorates Atopic Dermatitis in NC/Nga Mice via Th1 Polarization. <i>Journal of Immunology</i> , 2010, 184, 2729-2735.	0.4	64
244	PEGylated Adenoviruses: From Mice to Monkeys. <i>Viruses</i> , 2010, 2, 468-502.	1.5	50
245	Nanoparticles: Functionalization and Multifunctional Applications in Biomedical Sciences. <i>Current Medicinal Chemistry</i> , 2010, 17, 4559-4577.	1.2	261
246	Central nervous system delivery of large molecules: challenges and new frontiers for intrathecally administered therapeutics. <i>Expert Opinion on Drug Delivery</i> , 2010, 7, 285-293.	2.4	27

#	ARTICLE	IF	CITATIONS
247	Current Trends in Liposome Research. <i>Methods in Molecular Biology</i> , 2010, 605, 1-27.	0.4	87
248	Immunogenicity of therapeutics: a matter of efficacy and safety. <i>Expert Opinion on Drug Discovery</i> , 2010, 5, 1067-1079.	2.5	32
250	Do Differences in Pegylation of Interferon Alfa Matter?. <i>Gastroenterology</i> , 2010, 138, 34-36.	0.6	17
251	Self-Assembly of PEGylated Peptide Conjugates Containing a Modified Amyloid β -Peptide Fragment. <i>Langmuir</i> , 2010, 26, 9986-9996.	1.6	53
252	Immunoaffinity Purification Using Anti-PEG Antibody Followed by Two-Dimensional Liquid Chromatography/Tandem Mass Spectrometry for the Quantification of a PEGylated Therapeutic Peptide in Human Plasma. <i>Analytical Chemistry</i> , 2010, 82, 6877-6886.	3.2	65
253	Lymphatic Absorption of Quercetin and Rutin in Rat and Their Pharmacokinetics in Systemic Plasma. <i>Journal of Agricultural and Food Chemistry</i> , 2010, 58, 546-551.	2.4	46
254	Poly(ethylene glycol)-Protein, Peptide, and Enzyme Conjugates. , 2010, , 265-288.		3
255	Targeting gold nanocages to cancer cells for photothermal destruction and drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2010, 7, 577-587.	2.4	163
257	Protein PEGylation Attenuates Adsorption and Aggregation on a Negatively Charged and Moderately Hydrophobic Polymer Surface. <i>Langmuir</i> , 2010, 26, 18231-18238.	1.6	30
258	Pegylated interferons α 2a and α 2b in the treatment of chronic hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 485-494.	8.2	62
259	Effects of Modification of Amino Groups with Poly(Ethylene Glycol) on a Recombinant Uricase from <i>Bacillus fastidiosus</i> . <i>Bioscience, Biotechnology and Biochemistry</i> , 2010, 74, 1298-1301.	0.6	27
260	Interferon in the treatment of chronic hepatitis C: a drug caught between past and future. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 301-313.	1.4	15
261	Endosomal pH-Activatable Poly(ethylene oxide)-graft-Doxorubicin Prodrugs: Synthesis, Drug Release, and Biodistribution in Tumor-Bearing Mice. <i>Biomacromolecules</i> , 2011, 12, 1460-1467.	2.6	145
263	Evaluation of Bioactivity and Pharmacokinetic Characteristics of PEGylated <i>P.pastoris</i> -Expressed Erythropoietin. <i>Drug Delivery</i> , 2011, 18, 570-577.	2.5	10
264	Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or -2b to Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2011, 140, 459-468.e1.	0.6	132
265	Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?. <i>Immunopharmacology and Immunotoxicology</i> , 2011, 33, 744-750.	1.1	3
266	Synthetic Strategies for the Design of Peptide/Polymer Conjugates. <i>Polymer Reviews</i> , 2011, 51, 214-234.	5.3	77
267	In situ growth of a thermoresponsive polymer from a genetically engineered elastin-like polypeptide. <i>Polymer Chemistry</i> , 2011, 2, 1561.	1.9	16

#	ARTICLE	IF	CITATIONS
268	The Mechanism of Action of Interferon- β in Relapsing Multiple Sclerosis. <i>CNS Drugs</i> , 2011, 25, 491-502.	2.7	257
269	Pharmacokinetics and Pharmacodynamics of Pegfilgrastim. <i>Clinical Pharmacokinetics</i> , 2011, 50, 295-306.	1.6	122
271	Product development issues for PEGylated proteins. <i>Pharmaceutical Development and Technology</i> , 2011, 16, 423-440.	1.1	43
272	1990–2010: Two Decades of Interferon-Based Therapy. <i>Clinics in Liver Disease</i> , 2011, 15, 473-482.	1.0	8
273	PEGylated TNF-Related Apoptosis-Inducing Ligand (TRAIL) Analogues: Pharmacokinetics and Antitumor Effects. <i>Bioconjugate Chemistry</i> , 2011, 22, 1631-1637.	1.8	48
274	Membrane Pore Formation Induced by Acetylated and Polyethylene Glycol-Conjugated Polyamidoamine Dendrimers. <i>Journal of Physical Chemistry C</i> , 2011, 115, 5316-5322.	1.5	39
276	Metal Nanoparticles in Microbiology. , 2011, , .		81
277	The effect of GlycoPEGylation on the physical stability of human rFVIIa with increasing calcium chloride concentration. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2011, 78, 222-228.	2.0	5
278	Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties. <i>Nanomedicine</i> , 2011, 6, 1063-1084.	1.7	166
279	FDA-approved poly(ethylene glycol)–protein conjugate drugs. <i>Polymer Chemistry</i> , 2011, 2, 1442.	1.9	553
280	Coarse-Grained Model for PEGylated Lipids: Effect of PEGylation on the Size and Shape of Self-Assembled Structures. <i>Journal of Physical Chemistry B</i> , 2011, 115, 7830-7837.	1.2	104
281	The Conformation of the Poly(ethylene glycol) Chain in Mono-PEGylated Lysozyme and Mono-PEGylated Human Growth Hormone. <i>Bioconjugate Chemistry</i> , 2011, 22, 2317-2323.	1.8	80
282	Effects of PEGylation on the Size and Internal Structure of Dendrimers: Self-Penetration of Long PEG Chains into the Dendrimer Core. <i>Macromolecules</i> , 2011, 44, 2291-2298.	2.2	82
284	Photodynamic Antitumor Activity of Fullerene Modified with Poly(ethylene glycol) with Different Molecular Weights and Terminal Structures. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2011, 22, 297-312.	1.9	12
285	PLP-Dependent Enzymes: a Potent Therapeutic Approach for Cancer and Cardiovascular Diseases. , 0, , .		5
286	Targeted drug delivery to tumors: Myths, reality and possibility. <i>Journal of Controlled Release</i> , 2011, 153, 198-205.	4.8	1,580
287	Inorganic nanoparticles for cancer imaging and therapy. <i>Journal of Controlled Release</i> , 2011, 155, 344-357.	4.8	506
288	RAFT-synthesized graft copolymers that enhance pH-dependent membrane destabilization and protein circulation times. <i>Journal of Controlled Release</i> , 2011, 155, 167-174.	4.8	31

#	ARTICLE	IF	CITATIONS
289	A 4-arm polyethylene glycol derivative conjugated with exendin-4 peptide and palmitylamine having dual-function of size-increase and albumin-binding for long hypoglycemic action. <i>Regulatory Peptides</i> , 2011, 167, 239-245.	1.9	12
290	Positron Emission Tomography Imaging of Cancer Biology: Current Status and Future Prospects. <i>Seminars in Oncology</i> , 2011, 38, 70-86.	0.8	98
291	Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIg CALYPSO relapsing ovarian cancer trial. <i>Gynecologic Oncology</i> , 2011, 122, 226-232.	0.6	59
292	PEGylated recombinant von Willebrand factor analyzed by means of MALDI-TOF-MS, CGE-on-a-chip and nES-GEMMA. <i>International Journal of Mass Spectrometry</i> , 2011, 305, 157-163.	0.7	6
293	RAFT polymerization mediated bioconjugation strategies. <i>Polymer Chemistry</i> , 2011, 2, 1463.	1.9	53
294	Synthetic Modification of Carboxymethylcellulose and Use Thereof to Prepare a Nanoparticle Forming Conjugate of Docetaxel for Enhanced Cytotoxicity against Cancer Cells. <i>Bioconjugate Chemistry</i> , 2011, 22, 2474-2486.	1.8	86
295	Thermo- and pH-responsive hydrogel-coated gold nanoparticles prepared from rationally designed surface-confined initiators. <i>Journal of Nanoparticle Research</i> , 2011, 13, 2909-2918.	0.8	15
296	Nanotechnology for surgeons. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2011, 3, 223-228.	3.3	12
297	A Thermoresponsive Hydrogel Based on Telechelic PEG End-Capped with Hydrophobic Dipeptides. <i>Macromolecular Bioscience</i> , 2011, 11, 1068-1078.	2.1	40
298	Conjugation of siRNA with Comb-Type PEG Enhances Serum Stability and Gene Silencing Efficiency. <i>Macromolecular Rapid Communications</i> , 2011, 32, 654-659.	2.0	44
299	Synthesis, characterization, and drug-release behavior of novel PEGylated bovine serum albumin as a carrier for anticancer agents. <i>Journal of Applied Polymer Science</i> , 2011, 119, 2635-2643.	1.3	4
300	NMEGylation: A novel modification to enhance the bioavailability of therapeutic peptides. <i>Biopolymers</i> , 2011, 96, 688-693.	1.2	12
301	Synthesis and evaluation of cardiac glycoside mimics as potential anticancer drugs. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 2407-2417.	1.4	25
302	Stabilization of polyamidoamine (PAMAM) dendrimers/sodium dodecyl sulfate complexes via PEGylation. <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 2011, 380, 47-52.	2.3	11
303	Non-specific and specific interactions on functionalized polymer surface studied by FT-SPR. <i>Colloids and Surfaces B: Biointerfaces</i> , 2011, 83, 220-228.	2.5	12
304	PVA and BSA stabilized silver nanoparticles based surface-enhanced plasmon resonance probes for protein detection. <i>Colloids and Surfaces B: Biointerfaces</i> , 2011, 85, 138-144.	2.5	62
305	Biophysical characterisation of GlycoPEGylated recombinant human factor VIIa. <i>International Journal of Pharmaceutics</i> , 2011, 406, 62-68.	2.6	27
306	The molar hydrodynamic volume changes of factor VIIa due to GlycoPEGylation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 55, 597-602.	1.4	10

#	ARTICLE	IF	CITATIONS
308	Immunogenicity and other problems associated with the use of biopharmaceuticals. Therapeutic Advances in Drug Safety, 2011, 2, 113-128.	1.0	98
309	Ionic Liquid-Catalyzed Synthesis of Diethylene Glycol. Advanced Materials Research, 0, 549, 287-291.	0.3	2
310	Functionalization of Mesoporous Silicon Nanoparticles for Targeting and Bioimaging Purposes. Journal of Nanomaterials, 2012, 2012, 1-9.	1.5	52
311	A PEGylation Technology of L-Asparaginase with Monomethoxy Polyethylene Glycol-Propionaldehyde. Zeitschrift Fur Naturforschung - Section C Journal of Biosciences, 2012, 67, 312-318.	0.6	4
312	Nanoplexes for Cell Imaging and Hyperthermia: <>In Vitro</> Studies. Journal of Biomedical Nanotechnology, 2012, 8, 686-694.	0.5	8
313	Image-Guided Nanosystems for Targeted Delivery in Cancer Therapy. Current Medicinal Chemistry, 2012, 19, 3230-3240.	1.2	50
314	Bio-modified Fe₃O₄ core/Au shell nanoparticles for targeting and multimodal imaging of cancer cells. Journal of Materials Chemistry, 2012, 22, 470-477.	6.7	136
315	Emissive Behavior, Cytotoxic Activity, Cellular Uptake, and PEGylation Properties of New Luminescent Rhenium(I) Polypyridine Poly(ethylene glycol) Complexes. Inorganic Chemistry, 2012, 51, 13289-13302.	1.9	73
316	Isoform separation and binding site determination of mono-PEGylated lysozyme with pH gradient chromatography. Journal of Chromatography A, 2012, 1268, 102-108.	1.8	44
317	Zwitterionic reagents for labeling, cross-linking and improving the performance of chemiluminescent immunoassays. Organic and Biomolecular Chemistry, 2012, 10, 1883.	1.5	12
318	Nanotechnology: A Revolution in Cancer Diagnosis. Indian Journal of Clinical Biochemistry, 2012, 27, 214-220.	0.9	41
319	Quantifying the influence of polymer coatings on the serum albumin corona formation around silver and gold nanoparticles. Journal of Nanoparticle Research, 2012, 14, 1.	0.8	49
320	Solution Structural Characterization of Coiled-Coil Peptide"Polymer Side-Conjugates. Biomacromolecules, 2012, 13, 1945-1955.	2.6	32
321	Interactions of Liposome Carriers with Infectious Fungal Hyphae Reveals the Role of Î²-Glucans. Molecular Pharmaceutics, 2012, 9, 2489-2496.	2.3	9
322	Effects of the Size, Shape, and Structural Transition of Thermosensitive Polypeptides on the Stability of Lipid Bilayers and Liposomes. Macromolecules, 2012, 45, 7304-7312.	2.2	16
323	Design, modeling, and expression of erythropoietin cysteine analogs in Pichia pastoris: Improvement of mean residence times and in vivo activities through cysteine-specific PEGylation. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 80, 499-507.	2.0	12
324	PEGylation of Interferon-Î²-1a. CNS Drugs, 2012, 26, 205-214.	2.7	56
325	Oligomeric Poly(ethylene oxide)s. Functionalized Poly(ethylene glycol)s. PEGylation. , 2012, , 679-693.		2

#	ARTICLE	IF	CITATIONS
326	Nanoparticle encapsulated silvercarbene complexes and their antimicrobial and anticancer properties: A perspective. Dalton Transactions, 2012, 41, 327-336.	1.6	95
327	High-Throughput Discovery of Novel Steric Stabilizers for Cubic Lyotropic Liquid Crystal Nanoparticle Dispersions. Langmuir, 2012, 28, 9223-9232.	1.6	95
328	Improvement of drug safety by the use of lipid-based nanocarriers. Journal of Controlled Release, 2012, 163, 34-45.	4.8	244
329	Carbohydrate clearance receptors in transfusion medicine. Biochimica Et Biophysica Acta - General Subjects, 2012, 1820, 1797-1808.	1.1	22
330	Comparative studies of polyethylene glycol-modified liposomes prepared using different PEG-modification methods. Biochimica Et Biophysica Acta - Biomembranes, 2012, 1818, 2801-2807.	1.4	92
331	Comparative studies of irinotecan-loaded polyethylene glycol-modified liposomes prepared using different PEG-modification methods. Biochimica Et Biophysica Acta - Biomembranes, 2012, 1818, 2901-2907.	1.4	33
332	Evaluation of the Absolute Bioavailability of Pegylated Interferon Alfa-2a After Subcutaneous Administration to Healthy Male Volunteers: An Open-Label, Randomized, Parallel-Group Study. Clinical Therapeutics, 2012, 34, 1883-1891.	1.1	6
333	Prevention of Chemotherapy-Induced Neutropenia with Pegfilgrastim: Pharmacokinetics and Patient Outcomes. Chemotherapy, 2012, 58, 387-398.	0.8	31
334	VEGF-Functionalized Dextran Has Longer Intracellular Bioactivity than VEGF in Endothelial Cells. Biomacromolecules, 2012, 13, 2906-2916.	2.6	7
335	PEGylation Extends Circulation Half-Life While Preserving In Vitro and In Vivo Activity of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1). PLoS ONE, 2012, 7, e50028.	1.1	39
336	Poly(ester amide)-Poly(ethylene oxide) Graft Copolymers: Towards Micellar Drug Delivery Vehicles. International Journal of Polymer Science, 2012, 2012, 1-11.	1.2	12
337	Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. Journal of Peptide Science, 2012, 18, 383-393.	0.8	133
338	PEGylation of an artificial O ₂ and CO receptor: synthesis, characterisation and pharmacokinetic study. Organic and Biomolecular Chemistry, 2012, 10, 4337.	1.5	18
339	Heterobifunctional Poly(ethylene glycol) Derivatives for the Surface Modification of Gold Nanoparticles Toward Bone Mineral Targeting. Macromolecular Bioscience, 2012, 12, 1124-1136.	2.1	11
340	Interaction between PEO-b-PPO-b-PEO Copolymers and a Hexapeptide in Aqueous Solutions. Langmuir, 2012, 28, 1725-1732.	1.6	8
341	Advanced Materials for Co-Delivery of Drugs and Genes in Cancer Therapy. Advanced Healthcare Materials, 2012, 1, 373-392.	3.9	123
342	Modulators of Na/K-ATPase: a patent review. Expert Opinion on Therapeutic Patents, 2012, 22, 587-605.	2.4	49
343	Toward a molecular understanding of nanoparticle-protein interactions. Biophysical Reviews, 2012, 4, 137-147.	1.5	139

#	ARTICLE	IF	CITATIONS
344	Structural identification and biological activity of positional isomers of long-acting and mono-PEGylated recombinant human granulocyte colony-stimulating factor with trimeric-structured methoxy polyethylene glycol N-hydroxysuccinimidyl functional group. <i>Analytical Biochemistry</i> , 2012, 423, 286-293.	1.1	9
345	Comparative trials of peginterferon $\hat{I}\pm 2a$ and peginterferon $\hat{I}\pm 2b$ for chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012, 19, 37-41.	1.0	7
346	Novel analytical method to evaluate the surface condition of polyethylene glycol-modified liposomes. <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 2012, 397, 73-79.	2.3	14
347	Supramolecular assemblies in functional siRNA delivery: Where do we stand?. <i>Biomaterials</i> , 2012, 33, 2546-2569.	5.7	121
348	Exogenous fluorescent tracer agents based on pegylated pyrazine dyes for real-time point-of-care measurement of glomerular filtration rate. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 2490-2497.	1.4	33
349	Pharmacokinetics and pharmacodynamics of turoctocog alfa and $\langle scp \rangle N8 \langle /scp \rangle \hat{A} \langle scp \rangle GP \langle /scp \rangle$ in haemophilia $\langle scp \rangle A \langle /scp \rangle$ dogs. <i>Haemophilia</i> , 2012, 18, 941-947.	1.0	35
350	Preparation, characterization and in vitro bioactivity of N-terminally PEGylated staphylokinase dimers. <i>Process Biochemistry</i> , 2012, 47, 41-46.	1.8	18
351	PEGylation of interleukin-10 improves the pharmacokinetic profile and enhances the antifibrotic effectivity in CCl4-induced fibrogenesis in mice. <i>Journal of Controlled Release</i> , 2012, 162, 84-91.	4.8	20
352	Evaluation of the novel folate receptor ligand [18F]fluoro-PEG-folate for macrophage targeting in a rat model of arthritis. <i>Arthritis Research and Therapy</i> , 2013, 15, R37.	1.6	57
353	Nanoparticles as macromolecules. <i>Journal of Polymer Science, Part B: Polymer Physics</i> , 2013, 51, 1195-1208.	2.4	30
354	Advances in polymer and polymeric nanostructures for protein conjugation. <i>European Polymer Journal</i> , 2013, 49, 2906-2918.	2.6	31
355	Site-Specific PEGylation Enhances the Pharmacokinetic Properties and Antitumor Activity of Interferon Beta-1b. <i>Journal of Interferon and Cytokine Research</i> , 2013, 33, 769-777.	0.5	16
356	Plasmon \hat{A} resonant gold nanoparticles for cancer optical imaging. <i>Science China: Physics, Mechanics and Astronomy</i> , 2013, 56, 506-513.	2.0	17
357	Biologically Relevant Silver(I) \hat{A} Heterocyclic Carbene Complexes: Synthesis, Structure, Intramolecular Interactions, and Applications. <i>European Journal of Inorganic Chemistry</i> , 2013, 2013, 4367-4388.	1.0	108
358	Dendron \hat{A} polymer conjugates via the diels \hat{A} alder \hat{A} click \hat{A} reaction of novel anthracene \hat{A} based dendrons. <i>Journal of Polymer Science Part A</i> , 2013, 51, 3191-3201.	2.5	14
359	Molecular Dynamics Studies of PEGylated Single-Walled Carbon Nanotubes: The Effect of PEG Size and Grafting Density. <i>Journal of Physical Chemistry C</i> , 2013, 117, 26334-26341.	1.5	32
360	Endosomolytic Reducible Polymeric Electrolytes for Cytosolic Protein Delivery. <i>Biomacromolecules</i> , 2013, 14, 2570-2581.	2.6	20
361	18 \hat{A} F-click labeling and preclinical evaluation of a new 18 \hat{A} F-folate for PET imaging. <i>EJNMMI Research</i> , 2013, 3, 68.	1.1	15

#	ARTICLE	IF	CITATIONS
362	When the membrane is not enough: A simplified membrane cascade using Organic Solvent Nanofiltration (OSN). <i>Separation and Purification Technology</i> , 2013, 116, 277-286.	3.9	56
364	Bacteriophage associated silicon particles: design and characterization of a novel theranostic vector with improved payload carrying potential. <i>Journal of Materials Chemistry B</i> , 2013, 1, 5218.	2.9	20
365	Effect of PEGylation on Biodistribution and Gene Silencing of siRNA/Lipid Nanoparticle Complexes. <i>Pharmaceutical Research</i> , 2013, 30, 342-351.	1.7	81
366	Results of Treatment of Chronic Hepatitis B with Pegylated Interferon. <i>Clinics in Liver Disease</i> , 2013, 17, 425-443.	1.0	6
367	The LIF receptor antagonist PEGLA is effectively delivered to the uterine endometrium and blocks LIF activity in cynomolgus monkeys. <i>Contraception</i> , 2013, 87, 813-823.	0.8	11
368	Evaluation of new amphiphilic PEG derivatives for preparing stealth lipid nanoparticles. <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 2013, 434, 136-144.	2.3	23
369	Poly-(ethylene glycol) modified gelatin nanoparticles for sustained delivery of the anti-inflammatory drug Ibuprofen-Sodium: An in vitro and in vivo analysis. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2013, 9, 818-828.	1.7	74
370	Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?. <i>Liver International</i> , 2013, 33, 157-163.	1.9	17
371	Single-Site Mutational Engineering and Following MonoPEGylation of the Human Lectin Galectin-2: Effects on Ligand Binding, Functional Aspects, and Clearance from Serum. <i>Molecular Pharmaceutics</i> , 2013, 10, 2054-2061.	2.3	17
372	PegIFN-2a for the treatment of chronic hepatitis B and C: a 10-year history. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 459-474.	2.0	15
374	Engineering multifunctional nanoparticles: all-in-one versus one-for-all. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2013, 5, 250-265.	3.3	73
375	Polyethylenimines for siRNA and miRNA delivery in vivo. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2013, 5, 484-501.	3.3	166
376	Peptide-Polymer Conjugates: From Fundamental Science to Application. <i>Annual Review of Physical Chemistry</i> , 2013, 64, 631-657.	4.8	202
377	IL-1Ra and its Delivery Strategies: Inserting the Association in Perspective. <i>Pharmaceutical Research</i> , 2013, 30, 2951-2966.	1.7	55
378	PEG conjugated citrate-capped magnetite nanoparticles for biomedical applications. <i>Journal of Magnetism and Magnetic Materials</i> , 2013, 328, 91-95.	1.0	71
379	Generating functional mutant proteins to create highly bioactive anticancer biopharmaceuticals. , 2013, , 95-112.		0
380	Nanoscope Agents in a Physiological Environment: The Importance of Understanding Their Characteristics. <i>Topics in Medicinal Chemistry</i> , 2013, , 29-54.	0.4	3
381	Lymphatic Absorption, Metabolism, and Excretion of a Therapeutic Peptide in Dogs and Rats. <i>Drug Metabolism and Disposition</i> , 2013, 41, 2206-2214.	1.7	19

#	ARTICLE	IF	CITATIONS
382	Purification and analysis of mono-PEGylated HSA by hydrophobic interaction membrane chromatography. <i>Journal of Separation Science</i> , 2013, 36, 3673-3681.	1.3	13
383	Current Status and Prospects of Polyethyleneglycol-Modified Medicines. <i>Biological and Pharmaceutical Bulletin</i> , 2013, 36, 883-888.	0.6	18
384	<i>In Vivo</i> Pharmacokinetics and Pharmacodynamics of Positional Isomers of Mono-PEGylated Recombinant Human Granulocyte Colony Stimulating Factor in Rats. <i>Biological and Pharmaceutical Bulletin</i> , 2013, 36, 1146-1151.	0.6	7
385	Microspheres for Solid-Phase Organic Synthesis. , 2013, , 221-244.		0
386	Science and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists. <i>SAGE Open Medicine</i> , 2013, 1, 205031211351375.	0.7	47
387	Profile of certolizumab and its potential in the treatment of psoriatic arthritis. <i>Drug Design, Development and Therapy</i> , 2013, 7, 339.	2.0	25
388	Micro- and Nanoscale Delivery of Therapeutic Agents for Regenerative Therapy. , 0, , 127-156.		0
389	Surface Engineering of Liposomes for Stealth Behavior. <i>Pharmaceutics</i> , 2013, 5, 542-569.	2.0	235
390	Smart Biomaterials for Immunomodulation. <i>Drug Delivery System</i> , 2013, 28, 135-148.	0.0	0
391	Polymer Nanoparticles for Smart Drug Delivery. , 0, , .		71
392	Glycoengineering of Interferon- β 1a Improves Its Biophysical and Pharmacokinetic Properties. <i>PLoS ONE</i> , 2014, 9, e96967.	1.1	30
393	Polyethylene Glycol (PEG) Linked to Near Infrared (NIR) Dyes Conjugated to Chimeric Anti-Carcinoembryonic Antigen (CEA) Antibody Enhances Imaging of Liver Metastases in a Nude-Mouse Model of Human Colon Cancer. <i>PLoS ONE</i> , 2014, 9, e97965.	1.1	27
394	Covalent IR820-PEG-diamine nanoconjugates for theranostic applications in cancer. <i>International Journal of Nanomedicine</i> , 2014, 9, 4631.	3.3	32
395	Understanding nano-bio interactions to improve nanocarriers for drug delivery. <i>MRS Bulletin</i> , 2014, 39, 227-237.	1.7	50
396	Chemoselective PEGylation of cysteine analogs of human basic fibroblast growth factor (hbFGF) - design and expression. <i>Tropical Journal of Pharmaceutical Research</i> , 2014, 13, 1601.	0.2	1
397	Photothermal Therapy Using Gold Nanorods and Near-Infrared Light in a Murine Melanoma Model Increases Survival and Decreases Tumor Volume. <i>Journal of Nanomaterials</i> , 2014, 2014, 1-8.	1.5	30
398	Molecular Modeling of PEGylated Peptides, Dendrimers, and Single-Walled Carbon Nanotubes for Biomedical Applications. <i>Polymers</i> , 2014, 6, 776-798.	2.0	34
399	A Pharmacokinetic-Viral Kinetic Model Describes the Effect of Alisporivir as Monotherapy or in Combination With Peg-IFN on Hepatitis C Virologic Response. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 599-608.	2.3	10

#	ARTICLE	IF	CITATIONS
401	Polymer-Drug Conjugate in Focal Drug Delivery. <i>Advances in Delivery Science and Technology</i> , 2014, , 117-147.	0.4	4
402	A solid-phase PEGylation strategy for protein therapeutics using a potent FGF21 analog. <i>Biomaterials</i> , 2014, 35, 5206-5215.	5.7	28
403	A quantitative recipe for engineering protein polymer nanoparticles. <i>Polymer Chemistry</i> , 2014, 5, 1614-1625.	1.9	77
404	In vitro evaluation of polyethylene glycol based microparticles containing azithromycin. <i>Drug Delivery and Translational Research</i> , 2014, 4, 139-148.	3.0	3
405	Process for protein PEGylation. <i>Journal of Controlled Release</i> , 2014, 180, 134-149.	4.8	163
406	PEGylated HM-3 presents anti-rheumatic bioactivity by inhibiting angiogenesis and inflammation. <i>Journal of Materials Chemistry B</i> , 2014, 2, 800-813.	2.9	9
407	Dynamics and stability of lipid bilayers modulated by thermosensitive polypeptides, cholesterol, and PEGylated lipids. <i>Physical Chemistry Chemical Physics</i> , 2014, 16, 3763.	1.3	15
408	Water transverse relaxation rates in aqueous dispersions of superparamagnetic iron oxide nanoclusters with diverse hydrophilic coating. <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 2014, 443, 450-458.	2.3	17
409	Growing polymers from peptides and proteins: a biomedical perspective. <i>Polymer Chemistry</i> , 2014, 5, 266-276.	1.9	40
410	Pharmaceutical and Toxicological Properties of Engineered Nanomaterials for Drug Delivery. <i>Annual Review of Pharmacology and Toxicology</i> , 2014, 54, 581-598.	4.2	51
411	Proteins as substrates for controlled radical polymerization. <i>Polymer Chemistry</i> , 2014, 5, 1545-1558.	1.9	53
412	Engineered Nanoparticles for Drug Delivery in Cancer Therapy. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 12320-12364.	7.2	1,447
413	PEGylation Site-Dependent Structural Heterogeneity Study of MonoPEGylated Human Parathyroid Hormone Fragment hPTH(1-34). <i>Langmuir</i> , 2014, 30, 11421-11427.	1.6	2
414	PEGylation Improves the Pharmacokinetic Properties and Ability of Interferon Gamma to Inhibit Growth of a Human Tumor Xenograft in Athymic Mice. <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 759-768.	0.5	16
415	PEG - A versatile conjugating ligand for drugs and drug delivery systems. <i>Journal of Controlled Release</i> , 2014, 192, 67-81.	4.8	494
416	Model-based design and integration of a two-step biopharmaceutical production process. <i>Bioprocess and Biosystems Engineering</i> , 2014, 37, 1989-1996.	1.7	5
417	An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects. <i>Investigational New Drugs</i> , 2014, 32, 636-643.	1.2	8
418	Tailoring Polymersome Bilayer Permeability Improves Enhanced Permeability and Retention Effect for Bioimaging. <i>ACS Applied Materials & Interfaces</i> , 2014, 6, 10821-10829.	4.0	35

#	ARTICLE	IF	CITATIONS
419	Polymeric Materials in Drug Delivery. , 2014, , 333-349.		8
420	Molecular Dynamics Simulation of PEGylated Membranes with Cholesterol: Building Toward the DOXIL Formulation. Journal of Physical Chemistry C, 2014, 118, 15541-15549.	1.5	25
421	Peginterferon α 1 in the treatment of chronic hepatitis B. Expert Opinion on Biological Therapy, 2014, 14, 995-1006.	1.4	18
422	Evaluation of in vitro cytotoxic activity of mono-PEGylated StAP3 (Solanum tuberosum aspartic) Tj ETQq1 1 0.784314 rgBT /Overlock	2.1	1
423	Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics. Journal of Immunological Methods, 2014, 408, 1-12.	0.6	56
424	Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: Results of a prospective single-centre study. Advances in Medical Sciences, 2014, 59, 261-265.	0.9	2
425	Co-immobilization of PEGylated Aspergillus flavipes l-methioninase with glutamate dehydrogenase: A novel catalytically stable anticancer consortium. Enzyme and Microbial Technology, 2014, 54, 59-69.	1.6	35
426	Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. International Journal of Nanomedicine, 2014, 9, 2051.	3.3	19
428	Chronic inflammatory demyelinating polyneuropathy triggered by interferon α 1 for chronic hepatitis B virus infection. Neurology and Clinical Neuroscience, 2015, 3, 36-38.	0.2	1
431	PEGylated DOTA- α AHA-Based Gd ^{III} Chelates: A Relaxometric Study. European Journal of Inorganic Chemistry, 2015, 2015, 4798-4809.	1.0	5
432	Biochemical and Pharmacokinetic Properties of Aspergillus flavipes Glutathione-Homocystine Transhydrogenase of Unique Affinity for Homocystine Reduction using GSH as Hydrogen Donor. , 2015, 5, .		0
433	PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy. International Journal of Nanomedicine, 2015, 10, 739.	3.3	9
434	Nanoemulsion Based Targeting in Cancer Therapeutics. , 2015, 5, .		26
435	Preferential Interactions and the Effect of Protein PEGylation. PLoS ONE, 2015, 10, e0133584.	1.1	10
436	Targeting brain cells with glutathione-modulated nanoliposomes: in vitro and in vivo study. Drug Design, Development and Therapy, 2015, 9, 3705.	2.0	36
437	Protein corona " from molecular adsorption to physiological complexity. Beilstein Journal of Nanotechnology, 2015, 6, 857-873.	1.5	108
438	Efficacy of polyethylene glycol-conjugated bovine granulocyte colony-stimulating factor for reducing the incidence of naturally occurring clinical mastitis in periparturient dairy cows and heifers. American Journal of Veterinary Research, 2015, 76, 231-238.	0.3	27
439	The effect of protein corona on doxorubicin release from the magnetic mesoporous silica nanoparticles with polyethylene glycol coating. Journal of Nanoparticle Research, 2015, 17, 1.	0.8	19

#	ARTICLE	IF	CITATIONS
440	The Evolution Of Biotechnology And Its Impact On Health Care. Health Affairs, 2015, 34, 210-219.	2.5	46
441	Henipavirus pathogenesis and antiviral approaches. Expert Review of Anti-Infective Therapy, 2015, 13, 343-354.	2.0	34
442	Steric Stabilizers for Cubic Phase Lyotropic Liquid Crystal Nanodispersions (Cubosomes). Behavior Research Methods, 2015, , 131-187.	2.3	48
443	Liposomes Modified with Superhydrophilic Polymer Linked to a Nonphospholipid Anchor Exhibit Reduced Complement Activation and Enhanced Circulation. Journal of Pharmaceutical Sciences, 2015, 104, 114-123.	1.6	23
444	Gold Nanoparticles in Cancer Drug Delivery. , 2015, , 221-237.		9
445	Purification, immobilization, and biochemical characterization of <sc> </sc>â€arginine deiminase from thermophilic <i>Aspergillus fumigatus</i> <sc>KJ</sc>434941: Anticancer activity <i>in vitro</i>. Biotechnology Progress, 2015, 31, 396-405.	1.3	39
446	Impact of pegylation on biopharmaceutical properties of dendrimers. Polymer, 2015, 59, 67-92.	1.8	84
447	Facile synthesis of well-defined hydrophilic polyesters as degradable poly(ethylene glycol)-like biomaterials. Polymer Chemistry, 2015, 6, 6452-6456.	1.9	20
448	Targeted polymeric nanoparticles for cancer gene therapy. Journal of Drug Targeting, 2015, 23, 627-641.	2.1	41
450	Liposomes as nanomedical devices. International Journal of Nanomedicine, 2015, 10, 975.	3.3	1,579
451	Critical determinant of intestinal permeability and oral bioavailability of pegylated all trans-retinoic acid prodrug-based nanomicelles: Chain length of poly (ethylene glycol) corona. Colloids and Surfaces B: Biointerfaces, 2015, 130, 133-140.	2.5	20
452	Allergic sensitization to pegylated interferonâ€± results in drug eruptions. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 775-783.	2.7	16
453	Engineering chemically modified viruses for prostate cancer cell recognition. Molecular BioSystems, 2015, 11, 3264-3272.	2.9	4
454	Effect of lysozyme solid-phase PEGylation on reaction kinetics and isoform distribution. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 1002, 313-318.	1.2	16
455	Novel PEG-grafted nanostructured lipid carrier for systematic delivery of a poorly soluble anti-leukemia agent Tamibarotene: characterization and evaluation. Drug Delivery, 2015, 22, 223-229.	2.5	19
456	Dispersion and bilayer interaction of single-walled carbon nanotubes modulated by covalent and noncovalent PEGylation. Molecular Simulation, 2015, 41, 1254-1263.	0.9	10
457	The Effects of oil-in-Water Nanoemulsion Polyethylene Glycol Surface Density on Intracellular Stability, Pharmacokinetics, and Biodistribution in Tumor Bearing Mice. Pharmaceutical Research, 2015, 32, 1475-1485.	1.7	17
458	The Complexity of Protein Structure and the Challenges it Poses in Developing Biopharmaceuticals. , 2015, , 1-21.		3

#	ARTICLE	IF	CITATIONS
459	Therapeutic Alpha-Interferons Protein: Structure, Production, and Biosimilar. Preparative Biochemistry and Biotechnology, 2015, 45, 109-127.	1.0	26
460	Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes. Journal of Investigative Dermatology, 2015, 135, 31-38.	0.3	77
461	Soft Interaction in Liposome Nanocarriers for Therapeutic Drug Delivery. Nanomaterials, 2016, 6, 125.	1.9	125
462	Indocyanine Green Liposomes for Diagnosis and Therapeutic Monitoring of Cerebral Malaria. Theranostics, 2016, 6, 167-176.	4.6	22
463	Nanocarriers Usage for Drug Delivery in Cancer Therapy. Iranian Journal of Cancer Prevention, 2016, In Press, e3966.	0.7	50
464	Oral Squamous Cell Carcinoma: Current Treatment Strategies and Nanotechnology-Based Approaches for Prevention and Therapy. Critical Reviews in Therapeutic Drug Carrier Systems, 2016, 33, 363-400.	1.2	130
465	Mechanistic and quantitative insight into cell surface targeted molecular imaging agent design. Scientific Reports, 2016, 6, 25424.	1.6	27
466	Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial. Therapeutic Advances in Neurological Disorders, 2016, 9, 239-249.	1.5	27
467	Smart multifunctional nanoparticles in nanomedicine. BioNanoMaterials, 2016, 17, 33-41.	1.4	39
468	Improved antithrombotic activity and diminished bleeding side effect of a PEGylated Î±IIbÎ³3 antagonist, disintegrin. Thrombosis Research, 2016, 143, 3-10.	0.8	6
469	Exposure, tissue biodistribution, and biotransformation of nanosilver. NanoImpact, 2016, 2, 18-28.	2.4	24
470	Combined Magnesium/Polyethylene Glycol Facilitates the Neuroprotective Effects of Magnesium in Traumatic Brain Injury at a Reduced Magnesium Dose. CNS Neuroscience and Therapeutics, 2016, 22, 854-859.	1.9	9
471	Multi-functional vesicles for cancer therapy: The ultimate magic bullet. Colloids and Surfaces B: Biointerfaces, 2016, 147, 161-171.	2.5	64
472	Patterned Polypeptoid Brushes. Macromolecular Bioscience, 2016, 16, 75-81.	2.1	29
473	PEGylation of a High-Affinity Anti-(+)Methamphetamine Single Chain Antibody Fragment Extends Functional Half-Life by Reducing Clearance. Pharmaceutical Research, 2016, 33, 2954-2966.	1.7	6
474	Synthesis of Degradable Poly[(Ethylene Glycol)- <i>co</i> -(Glycolic Acid)] via the Post-Polymerization Oxyfunctionalization of Poly(Ethylene Glycol). Macromolecular Rapid Communications, 2016, 37, 1587-1592.	2.0	16
475	PEGylated PAMAM dendrimers: Enhancing efficacy and mitigating toxicity for effective anticancer drug and gene delivery. Acta Biomaterialia, 2016, 43, 14-29.	4.1	296
476	Dynamically Tunable Smart Nanodrug Perspectives: Promises and challenges of nanoparticle-based drug delivery.. IEEE Nanotechnology Magazine, 2016, 10, 29-39.	0.9	0

#	ARTICLE	IF	CITATIONS
477	Engineered gold nanoparticles for photothermal cancer therapy and bacteria killing. RSC Advances, 2016, 6, 111482-111516.	1.7	62
478	Nanocarrier-Based Anticancer Therapies with the Focus on Strategies for Targeting the Tumor Microenvironment. Fundamental Biomedical Technologies, 2016, , 67-122.	0.2	0
479	Modeling and Optimization of Protein PEGylation. Industrial & Engineering Chemistry Research, 2016, 55, 11785-11794.	1.8	7
480	Adsorption of Plasma Proteins onto PEGylated Lipid Bilayers: The Effect of PEG Size and Grafting Density. Biomacromolecules, 2016, 17, 1757-1765.	2.6	75
481	“Graft-to” Protein/Polymer Conjugates Using Polynorbornene Block Copolymers. Biomacromolecules, 2016, 17, 641-648.	2.6	39
482	Review on photoacoustic imaging of the brain using nanoprobes. Neurophotonics, 2016, 3, 010901.	1.7	76
483	Fabrication of electrospun poly(ethylene oxide)“poly(caprolactone) composite nanofibers for co-delivery of niclosamide and silver nanoparticles exhibits enhanced anti-cancer effects in vitro. Journal of Materials Chemistry B, 2016, 4, 726-742.	2.9	63
484	Modification with polysialic acid“PEG copolymer as a new method for improving the therapeutic efficacy of proteins. Preparative Biochemistry and Biotechnology, 2016, 46, 788-797.	1.0	5
485	The Pharmacokinetics and Biodistribution of a 64 kDa PolyPEG Star Polymer After Subcutaneous and Pulmonary Administration to Rats. Journal of Pharmaceutical Sciences, 2016, 105, 293-300.	1.6	17
486	Targeted delivery of growth factors in ischemic stroke animal models. Expert Opinion on Drug Delivery, 2016, 13, 709-723.	2.4	12
487	Antigen delivery via hydrophilic PEG- b -PAGE- b -PLGA nanoparticles boosts vaccination induced T cell immunity. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 102, 20-31.	2.0	47
488	Growth inhibitory effect of an injectable hyaluronic acid“tyramine hydrogels incorporating human natural interferon- β and sorafenib on renal cell carcinoma cells. Acta Biomaterialia, 2016, 29, 103-111.	4.1	42
489	PEGylation Enhances Mosquito-Larvicidal Activity of <i>Lysinibacillus sphaericus</i> Binary Toxin. Bioconjugate Chemistry, 2017, 28, 410-418.	1.8	8
490	Polymer-based drug delivery: the quest for local targeting of inflamed intestinal mucosa. Journal of Drug Targeting, 2017, 25, 582-596.	2.1	29
491	A pH-Responsive Detachable PEG Shielding Strategy for Gene Delivery System in Cancer Therapy. Biomacromolecules, 2017, 18, 1342-1349.	2.6	113
492	Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview. Drugs, 2017, 77, 363-377.	4.9	33
493	A traceless reversible polymeric colistin prodrug to combat multidrug-resistant (MDR) gram-negative bacteria. Journal of Controlled Release, 2017, 259, 83-91.	4.8	15
494	Cholesterol“PEG comodified poly (<i>N</i> -butyl) cyanoacrylate nanoparticles for brain delivery: <i>in vitro</i> and <i>in vivo</i> evaluations. Drug Delivery, 2017, 24, 121-132.	2.5	29

#	ARTICLE	IF	CITATIONS
495	A Bayesian Approach for Population Pharmacokinetic Modeling of Pegylated Interferon α -2a in Hepatitis C Patients. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1369-1379.	1.6	5
496	Synthesis of novel PEG-modified nitroimidazole derivatives via "hot-click" reaction and their biological evaluation as potential PET imaging agent for tumors. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2017, 312, 263-276.	0.7	9
497	Adsorption of plasma proteins onto PEGylated single-walled carbon nanotubes: The effects of protein shape, PEG size and grafting density. <i>Journal of Molecular Graphics and Modelling</i> , 2017, 75, 1-8.	1.3	11
498	Post-polymerization functionalization of poly(ethylene oxide)-poly(ϵ -caprolactone) diblock copolymers to tune properties and self-assembly. <i>Polymer Chemistry</i> , 2017, 8, 557-567.	1.9	11
499	PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application. <i>Journal of Controlled Release</i> , 2017, 260, 46-60.	4.8	335
500	Perspectives on dendritic architectures and their biological applications: From core to cell. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2017, 173, 61-83.	1.7	13
501	Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1841-1847.	1.3	15
502	A brain-sparing diphtheria toxin for chemical genetic ablation of peripheral cell lineages. <i>Nature Communications</i> , 2017, 8, 14967.	5.8	28
503	Poly(ethyl glyoxylate)-Poly(ethylene oxide) Nanoparticles: Stimuli-Responsive Drug Release via End-to-End Polyglyoxylate Depolymerization. <i>Molecular Pharmaceutics</i> , 2017, 14, 2548-2559.	2.3	56
504	Metal-phenolic networks as a versatile platform to engineer nanomaterials and biointerfaces. <i>Nano Today</i> , 2017, 12, 136-148.	6.2	411
505	Lithography-based methods to manufacture biomaterials at small scales. <i>Journal of Science: Advanced Materials and Devices</i> , 2017, 2, 1-14.	1.5	84
506	Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system. <i>Scientific Reports</i> , 2017, 7, 14177.	1.6	23
507	Effect of Poly(ethylene glycol) on the Ultrastructure and Physicochemical Properties of the Poly(3-hydroxybutyrate). <i>Macromolecular Symposia</i> , 2017, 375, 1600189.	0.4	6
508	Polyethylene Glycol Based Changes to β -Sheet Protein Conformational and Proteolytic Stability Depend on Conjugation Strategy and Location. <i>Bioconjugate Chemistry</i> , 2017, 28, 2507-2513.	1.8	9
509	Folate-PEG Conjugates of a Far-Red Light-Activatable Paclitaxel Prodrug to Improve Selectivity toward Folate Receptor-Positive Cancer Cells. <i>ACS Omega</i> , 2017, 2, 6349-6360.	1.6	41
511	Small Angle Scattering for Pharmaceutical Applications: From Drugs to Drug Delivery Systems. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1009, 239-262.	0.8	7
512	Biological Molecules in Therapeutic Nanodevices. <i>Springer Handbooks</i> , 2017, , 693-722.	0.3	1
513	Nanoparticle-macrophage interactions: A balance between clearance and cell-specific targeting. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 4487-4496.	1.4	52

#	ARTICLE	IF	CITATIONS
514	An Overview on Advances in the Nanocarriers Drug Delivery Systems. <i>Advanced Structured Materials</i> , 2017, , 65-76.	0.3	4
515	Dissipative particle dynamics parameterization and simulations to predict negative volume excess and structure of PEG and water mixtures. <i>Chemical Physics Letters</i> , 2017, 690, 133-139.	1.2	9
516	Influence of Physicochemical Properties and PEG Modification of Magnetic Liposomes on Their Interaction with Intestinal Epithelial Caco-2 Cells. <i>Biological and Pharmaceutical Bulletin</i> , 2017, 40, 2166-2174.	0.6	9
517	Relationship among reaction rate, release rate and efficiency of nanomachine-based targeted drug delivery. <i>Technology and Health Care</i> , 2017, 25, 1119-1130.	0.5	3
518	Electrospinning of hybrid nanofibres elaborated with PEG core dendrimers and SPIONs synthesized in-situ: As multifunctional material for biomedical applications. , 2017, , .		0
519	Nanoarmored Enzymes for Organic Enzymology. <i>Methods in Enzymology</i> , 2017, 590, 413-444.	0.4	1
520	Functionalization of nanoparticles inÂspecific targeting andÂmechanism release. , 2017, , 57-80.		14
521	RNAi therapy to the wall of arteries and veins: anatomical, physiologic, and pharmacological considerations. <i>Journal of Translational Medicine</i> , 2017, 15, 164.	1.8	12
522	Physiology and Pathology of Cytokine: Commercial Production and Medical Use. , 2017, , .		2
523	Multifunctional nanosized emulsions for theragnosis of life threatening diseases. , 2017, , 579-617.		3
524	Evidence of Protein Adsorption in Pegylated Liposomes: Influence of Liposomal Decoration. <i>Nanomaterials</i> , 2017, 7, 37.	1.9	19
525	Basic Principles of Formulation for Biotherapeutics: Approaches to Alternative Drug Delivery. , 2017, , 131-156.		0
526	Clinical studies and future prospects. , 2017, , 219-232.		0
527	Luminescent rhenium(I), ruthenium(II), and iridium(III) polypyridine complexes containing a poly(ethylene glycol) pendant or bioorthogonal reaction group as biological probes and photocytotoxic agents. <i>Coordination Chemistry Reviews</i> , 2018, 361, 138-163.	9.5	101
528	On-target and direct modulation of alloreactive T cells by a nanoparticle carrying MHC alloantigen, regulatory molecules and CD47 in a murine model of alloskin transplantation. <i>Drug Delivery</i> , 2018, 25, 703-715.	2.5	21
529	Cytocompatibility and Cellular Internalization of PEGylated âœClickableâœ•Nucleic Acid Oligomers. <i>Biomacromolecules</i> , 2018, 19, 2535-2541.	2.6	8
530	Mesoporous lipid-silica nanohybrids for folate-targeted drug-resistant ovarian cancer. <i>New Journal of Chemistry</i> , 2018, 42, 2804-2814.	1.4	11
531	Cholinesterases and the fine line between poison and remedy. <i>Biochemical Pharmacology</i> , 2018, 153, 205-216.	2.0	85

#	ARTICLE	IF	CITATIONS
532	High-density lipoprotein-mimicking nanodiscs carrying peptide for enhanced therapeutic angiogenesis in diabetic hindlimb ischemia. <i>Biomaterials</i> , 2018, 161, 69-80.	5.7	29
533	Exosomes Serve as Nanoparticles to Deliver Anti-miR-214 to Reverse Chemoresistance to Cisplatin in Gastric Cancer. <i>Molecular Therapy</i> , 2018, 26, 774-783.	3.7	157
534	Concise Review: Fabrication, Customization, and Application of Cell Mimicking Microparticles in Stem Cell Science. <i>Stem Cells Translational Medicine</i> , 2018, 7, 232-240.	1.6	15
535	The Locational Impact of Site-Specific PEGylation: Streamlined Screening with Cell-Free Protein Expression and Coarse-Grain Simulation. <i>ACS Synthetic Biology</i> , 2018, 7, 510-521.	1.9	36
536	Chemical modification of protein A chromatography ligands with polyethylene glycol. I: Effects on IgG adsorption equilibrium, kinetics, and transport. <i>Journal of Chromatography A</i> , 2018, 1546, 77-88.	1.8	5
537	Chemical modification of protein a chromatography ligands with polyethylene glycol. II: Effects on resin robustness and process selectivity. <i>Journal of Chromatography A</i> , 2018, 1546, 89-96.	1.8	3
538	Characterisation of the site-specific monoPEGylated rhG-CSF analogue pegteograstim. <i>Biologicals</i> , 2018, 51, 54-61.	0.5	11
539	Synthesis and Characterization of Folate-Decorated Cobalt Ferrite Nanoparticles Coated with Poly(Ethylene Glycol) for Biomedical Applications. <i>Journal of the Chinese Chemical Society</i> , 2018, 65, 231-242.	0.8	19
540	Preparation and comparative evaluation of ^{99m}Tc -HYNIC-NGR and ^{99m}Tc -HYNIC-PEG ₂ -NGR as tumor-targeting molecular imaging probes. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2018, 61, 68-76.	0.5	4
541	Multifunctional quantum dots and liposome complexes in drug delivery. <i>Journal of Biomedical Research</i> , 2018, 32, 91.	0.7	29
542	Stapling of two PEGylated side chains increases the conformational stability of the WW domain via an entropic effect. <i>Organic and Biomolecular Chemistry</i> , 2018, 16, 8933-8939.	1.5	7
543	Doxorubicin-Loaded PEG-CdTe Quantum Dots as a Smart Drug Delivery System for Extramedullary Multiple Myeloma Treatment. <i>Nanoscale Research Letters</i> , 2018, 13, 373.	3.1	22
544	PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2018, 9, 2413.	2.2	14
545	The promising antitumour drug disulfiram inhibits viability and induces apoptosis in cardiomyocytes. <i>Biomedicine and Pharmacotherapy</i> , 2018, 108, 1062-1069.	2.5	6
546	Impact of Polymer Bioconjugation on Protein Stability and Activity Investigated with Discrete Conjugates: Alternatives to PEGylation. <i>Biomacromolecules</i> , 2018, 19, 4250-4262.	2.6	35
547	PEGylation of therapeutic oligonucleotides: From linear to highly branched PEG architectures. <i>Nano Research</i> , 2018, 11, 5519-5534.	5.8	36
548	Analyzing PEGylation through Molecular Dynamics Simulations. <i>ChemistrySelect</i> , 2018, 3, 8415-8427.	0.7	14
549	Nanoparticles as carriers for drug delivery in cancer. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 295-305.	1.9	193

#	ARTICLE	IF	CITATIONS
550	Molecular Consortiaâ€™ Various Structural and Synthetic Concepts for More Effective Therapeutics Synthesis. International Journal of Molecular Sciences, 2018, 19, 1104.	1.8	52
551	The effects of gold nanoparticles on the human blood functions. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 720-726.	1.9	22
552	Molecular dynamics simulation for rational protein engineering: Present and future prospectus. Journal of Molecular Graphics and Modelling, 2018, 84, 43-53.	1.3	23
553	Sterically stabilized siRNA:gold nanocomplexes enhance <i>c-MYC</i> silencing in a breast cancer cell model. Nanomedicine, 2019, 14, 1387-1401.	1.7	42
554	In vitro study of the cytotoxicity of thymoquinone/curcumin fluorescent liposomes. Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392, 1465-1476.	1.4	13
555	Synthesis and bioevaluation of novel radioiodinated PEG-modified 2-nitroimidazole derivatives for tumor hypoxia imaging. Journal of Radioanalytical and Nuclear Chemistry, 2019, 321, 943-954.	0.7	6
556	A multifunctional biodegradable brush polymer-drug conjugate for paclitaxel/gemcitabine co-delivery and tumor imaging. Nanoscale Advances, 2019, 1, 2761-2771.	2.2	16
557	Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 779-785.	1.5	21
558	Adverse vacuolation in multiple tissues in cynomolgus monkeys following repeat-dose administration of a PEGylated protein. Toxicology Letters, 2019, 317, 120-129.	0.4	20
559	Polymeric Nanomaterials. , 2019, , 1-66.		25
560	Progress in the application of exosomes as therapeutic vectors in tumor-targeted therapy. Cytotherapy, 2019, 21, 509-524.	0.3	24
561	PEGylated substance P augments therapeutic angiogenesis in diabetic critical limb ischemia. Journal of Industrial and Engineering Chemistry, 2019, 78, 396-409.	2.9	8
562	Influence of PEGylation on the Strength of Protein Surface Salt Bridges. ACS Chemical Biology, 2019, 14, 1652-1659.	1.6	8
563	A new approach for drug targeting to the central nervous system. , 2019, , 335-369.		2
564	Topical application of polymeric nanomicelles in ophthalmology: a review on research efforts for the noninvasive delivery of ocular therapeutics. Expert Opinion on Drug Delivery, 2019, 16, 397-413.	2.4	57
565	Synthesis, spectroscopic properties, thermal properties and aggregation behaviors of macrogol-substituted phthalocyanines. Journal of Molecular Structure, 2019, 1187, 121-131.	1.8	12
566	Smart Nanoparticles for Drug Delivery Application: Development of Versatile Nanocarrier Platforms in Biotechnology and Nanomedicine. Journal of Nanomaterials, 2019, 2019, 1-26.	1.5	570
567	Pharmacokinetics of 40â€‰kDa PEG in rodents using high-field NMR spectroscopy. Journal of Pharmaceutical and Biomedical Analysis, 2019, 171, 30-34.	1.4	6

#	ARTICLE	IF	CITATIONS
568	Surface Modifications of Liposomes for Drug Targeting. , 2019, , 207-220.		4
569	From Synthesis to Characterization of Site-Selective PEGylated Proteins. <i>Frontiers in Pharmacology</i> , 2019, 10, 1450.	1.6	29
570	Immunoaffinity LC-MS/MS to quantify a PEGylated anti-Factor D Fab biotherapeutic in cynomolgus monkey serum. <i>Bioanalysis</i> , 2019, 11, 2161-2173.	0.6	7
571	IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies. <i>PLoS Pathogens</i> , 2019, 15, e1008082.	2.1	16
572	A review of lipidation in the development of advanced protein and peptide therapeutics. <i>Journal of Controlled Release</i> , 2019, 295, 1-12.	4.8	77
573	Long circulating genetically encoded intrinsically disordered zwitterionic polypeptides for drug delivery. <i>Biomaterials</i> , 2019, 192, 475-485.	5.7	68
574	Zwitterionic poly(carboxybetaine) functionalized conducting polymer polyaniline nanowires for the electrochemical detection of carcinoembryonic antigen in undiluted blood serum. <i>Bioelectrochemistry</i> , 2019, 125, 90-96.	2.4	39
575	Characterization and optimization of immunoaffinity aqueous two-phase systems with PEGylated CD133/2â€biotin antibody in route to stem cell separation. <i>Journal of Chemical Technology and Biotechnology</i> , 2020, 95, 123-131.	1.6	3
576	Evaluating the ion exchange chromatography for matrixâ€assisted PEGylation and purification of consensus interferon. <i>Biotechnology and Applied Biochemistry</i> , 2020, 67, 196-205.	1.4	2
577	The complexity of protein structure and the challenges it poses in developing biopharmaceuticals. , 2020, , 3-26.		2
578	Immunogenicity assessment of PEGylated proteins, Lonquex, a PEGylated G-CSF case study. , 2020, , 125-140.		1
579	Design and Optimization of PLGA Particles to Deliver Immunomodulatory Drugs for the Prevention of Skin Allograft Rejection. <i>Immunological Investigations</i> , 2020, 49, 840-857.	1.0	11
580	20 kDa PEGylated Adrenomedullin as a New Therapeutic Candidate for Inflammatory Bowel Disease. <i>Gastrointestinal Disorders</i> , 2020, 2, 366-377.	0.4	2
581	Rational design of a fluorescent microneedle tattoo for minimally invasive monitoring of lymphatic function. <i>Journal of Controlled Release</i> , 2020, 327, 350-359.	4.8	15
582	The Biomolecular Corona of Lipid Nanoparticles for Gene Therapy. <i>Bioconjugate Chemistry</i> , 2020, 31, 2046-2059.	1.8	120
583	Characterisation of recombinant factor IX before and after GlycoPEGylation. <i>International Journal of Pharmaceutics</i> , 2020, 588, 119654.	2.6	5
584	Engineering Smart Targeting Nanovesicles and Their Combination with Hydrogels for Controlled Drug Delivery. <i>Pharmaceutics</i> , 2020, 12, 849.	2.0	75
585	PEGylated graphene oxide as a nanocarrier of the disulfide prodrug of podophyllotoxin for cancer therapy. <i>Journal of Nanoparticle Research</i> , 2020, 22, 1.	0.8	9

#	ARTICLE	IF	CITATIONS
586	Molecular Simulations of PEGylated Biomolecules, Liposomes, and Nanoparticles for Drug Delivery Applications. <i>Pharmaceutics</i> , 2020, 12, 533.	2.0	38
587	Targeting drug delivery in the vascular system: Focus on endothelium. <i>Advanced Drug Delivery Reviews</i> , 2020, 157, 96-117.	6.6	61
588	Interactions at the cell membrane and pathways of internalization of nano-sized materials for nanomedicine. <i>Beilstein Journal of Nanotechnology</i> , 2020, 11, 338-353.	1.5	80
589	Adrenomedullin – Current perspective on a peptide hormone with significant therapeutic potential. <i>Peptides</i> , 2020, 131, 170347.	1.2	23
590	Dimerization-induced self-assembly of a redox-responsive prodrug into nanoparticles for improved therapeutic index. <i>Acta Biomaterialia</i> , 2020, 113, 464-477.	4.1	31
591	Improved Antithrombotic Activity and Diminished Bleeding Side Effect of a PEGylated α -IIb β 3 Antagonist, Disintegrin. <i>Toxins</i> , 2020, 12, 426.	1.5	8
592	PEGylated liposomes as an emerging therapeutic platform for oral nanomedicine in cancer therapy: in vitro and in vivo assessment. <i>Journal of Molecular Liquids</i> , 2020, 303, 112649.	2.3	51
593	Nanochaperones Mediated Delivery of Insulin. <i>Nano Letters</i> , 2020, 20, 1755-1765.	4.5	28
594	Tumor-targeting and redox-sensitive micelles based on hyaluronic acid conjugate for delivery of paclitaxel. <i>Journal of Biomaterials Applications</i> , 2020, 34, 1458-1469.	1.2	10
595	A Chitosan-Based Micellar System as Nanocarrier For the Delivery of Paclitaxel. <i>Polymers</i> , 2020, 12, 380.	2.0	16
596	Site Directed Disulfide PEGylation of Interferon- β -1b with Fork Peptide Linker. <i>Bioconjugate Chemistry</i> , 2020, 31, 708-720.	1.8	0
597	Effects of Nanoparticle Electrostatics and Protein-Protein Interactions on Corona Formation: Conformation and Hydrodynamics. <i>Small</i> , 2020, 16, e1906598.	5.2	37
598	Defining the Design Parameters for <i>in Vivo</i> Enzyme Delivery Through Protein Spherical Nucleic Acids. <i>ACS Central Science</i> , 2020, 6, 815-822.	5.3	28
599	Multifunctional micelles self-assembled from hyaluronic acid conjugate for enhancing anti-tumor effect of paclitaxel. <i>Reactive and Functional Polymers</i> , 2020, 152, 104608.	2.0	23
600	Superhydrophilicity and strong salt-affinity: Zwitterionic polymer grafted surfaces with significant potentials particularly in biological systems. <i>Advances in Colloid and Interface Science</i> , 2020, 278, 102141.	7.0	72
601	Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 291-298.	0.8	3
602	Perfluorocarbon-based oxygen carriers: from physics to physiology. <i>Pflügers Archiv European Journal of Physiology</i> , 2021, 473, 139-150.	1.3	98
603	Gain an advantage from both sides: Smart size-shrinkable drug delivery nanosystems for high accumulation and deep penetration. <i>Nano Today</i> , 2021, 36, 101038.	6.2	54

#	ARTICLE	IF	CITATIONS
604	Synthesis of PEGylated nanographene oxide as a nanocarrier for docetaxel drugs and anticancer activity on prostate cancer cell lines. <i>Human and Experimental Toxicology</i> , 2021, 40, 172-182.	1.1	20
605	Live-cell epigenome manipulation by synthetic histone acetylation catalyst system. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	24
606	Tumor Vasculature. , 2021, , 831-867.		1
607	Bacterial Genotoxin-Coated Nanoparticles for Radiotherapy Sensitization in Prostate Cancer. <i>Biomedicines</i> , 2021, 9, 151.	1.4	7
608	Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy. <i>BMC Cancer</i> , 2021, 21, 341.	1.1	3
609	Probing the Interactions of Porphyrins with Macromolecules Using NMR Spectroscopy Techniques. <i>Molecules</i> , 2021, 26, 1942.	1.7	19
610	Inhalable PLGA microspheres: Tunable lung retention and systemic exposure via polyethylene glycol modification. <i>Acta Biomaterialia</i> , 2021, 123, 325-334.	4.1	22
611	Simultaneous crosslinking induces macroscopically phase-separated microgel from a homogeneous mixture of multiple polymers. <i>Applied Materials Today</i> , 2021, 22, 100937.	2.3	8
612	Genetic Code Expansion: Inception, Development, Commercialization. <i>Journal of the American Chemical Society</i> , 2021, 143, 4859-4878.	6.6	49
613	Clinical Relevance of Pre-Existing and Treatment-Induced Anti-Poly(Ethylene Glycol) Antibodies. <i>Regenerative Engineering and Translational Medicine</i> , 2022, 8, 32-42.	1.6	35
614	Encapsulation and Delivery of Dimethylcurcumin by Using Nanoparticles of a Polyethyleneâ€Glycolâ€Based Dimethylcurcumin Prodrug. <i>ChemistrySelect</i> , 2021, 6, 3013-3021.	0.7	3
615	Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles. <i>Advanced Science</i> , 2021, 8, e2002085.	5.6	25
616	The evolution of commercial drug delivery technologies. <i>Nature Biomedical Engineering</i> , 2021, 5, 951-967.	11.6	539
617	Incorporating Gangliosides into PEGylated Cationic Liposomes that Complexed DNA Attenuates Anti-PEG Antibody Production but Not Anti-DNA Antibody Production in Mice. <i>Molecular Pharmaceutics</i> , 2021, 18, 2406-2415.	2.3	4
618	The Influence of a Polyethylene Glycol Linker on the Metabolism and Pharmacokinetics of a ⁸⁹ Zr-Radiolabeled Antibody. <i>Bioconjugate Chemistry</i> , 2021, 32, 1263-1275.	1.8	15
619	Poly ethylene glycol (PEG)-Related controllable and sustainable antidiabetic drug delivery systems. <i>European Journal of Medicinal Chemistry</i> , 2021, 217, 113372.	2.6	35
620	Genetically Encoded Elastinâ€Like Polypeptides for Drug Delivery. <i>Advanced Healthcare Materials</i> , 2021, 10, e2100209.	3.9	30
621	Long Circulation of PEG-TRAIL Improves Anti-Hepatic Fibrosis Effect of TRAIL Via Targeting Activated Hepatic Stellate Cells. <i>Frontiers in Materials</i> , 2021, 8, .	1.2	1

#	ARTICLE	IF	CITATIONS
622	From Nanoparticles to Cancer Nanomedicine: Old Problems with New Solutions. <i>Nanomaterials</i> , 2021, 11, 1727.	1.9	25
623	PEGylation of the Antimicrobial Peptide PG-1: A Link between Propensity for Nanostructuring and Capacity of the Antitrypsin Hydrolytic Ability. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10469-10481.	2.9	22
624	Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature. <i>Gynecologic Oncology</i> , 2021, 162, 80-87.	0.6	5
625	Nanotechnology-Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID-19 Vaccines. <i>Small Methods</i> , 2021, 5, 2100402.	4.6	45
626	Impact of injection sites on clinical pharmacokinetics of subcutaneously administered peptides and proteins. <i>Journal of Controlled Release</i> , 2021, 336, 310-321.	4.8	22
627	Microfluidic Formulation of DNA-Loaded Multicomponent Lipid Nanoparticles for Gene Delivery. <i>Pharmaceutics</i> , 2021, 13, 1292.	2.0	25
628	Fast and high-resolution purification of a PEGylated protein using a 22 laterally-fed membrane chromatography device. <i>Journal of Chromatography A</i> , 2021, 1652, 462375.	1.8	5
629	Liposomes-based Nanoplatfom Enlarges Ultrasound-related Diagnostic and Therapeutic Precision. <i>Current Medicinal Chemistry</i> , 2022, 29, 1331-1341.	1.2	3
630	Direct measurement of surface forces: Recent advances and insights. <i>Applied Physics Reviews</i> , 2021, 8, .	5.5	6
633	Therapeutic Nanodevices. , 2004, , 279-322.		4
634	Nanodevices in Biomedical Applications. , 2006, , 363-398.		4
635	Protocol for Simulations of PEGylated Proteins with Martini 3. <i>Methods in Molecular Biology</i> , 2021, 2199, 315-335.	0.4	10
636	Polymer-Based Delivery of RNA-Based Therapeutics in Ovarian Cancer. <i>Methods in Molecular Biology</i> , 2013, 1049, 443-465.	0.4	3
637	Application of Nanotechnology in Diagnosis and Therapeutics. <i>Green Energy and Technology</i> , 2020, , 413-440.	0.4	5
638	The Safety Profile of Filgrastim and Pegfilgrastim. , 2012, , 395-408.		3
639	Lipid- and Polymer-Based Drug Delivery Carriers for Eradicating Microbial Biofilms Causing Medical Device-Related Infections. <i>Advances in Experimental Medicine and Biology</i> , 2015, 831, 147-189.	0.8	4
640	Noninvasive Tracer Techniques to Characterize Angiogenesis. <i>Handbook of Experimental Pharmacology</i> , 2008, , 323-339.	0.9	7
641	Biological Molecules in Therapeutic Nanodevices. , 2010, , 453-484.		3

#	ARTICLE	IF	CITATIONS
642	Suppressive effect upon carboplatin hypersensitivity reaction via pegylated liposomal doxorubicin combination therapy. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1718-1725.	1.0	3
643	Nanotechnology and primary hemostasis: Differential effects of nanoparticles on platelet responses. <i>Vascular Pharmacology</i> , 2018, 101, 1-8.	1.0	34
644	Pharmacokinetics of Protein- and Nucleotide-Based Drugs. , 2004, , .		2
645	Advances in Polymeric and Lipid-Core Micelles as Drug Delivery Systems. , 2013, , 65-84.		1
646	Effect of Different Interferon- β Preparations on IP10 and ET-1 Release from Human Lung Cells. <i>PLoS ONE</i> , 2012, 7, e46779.	1.1	13
647	Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In Vivo. <i>PLoS ONE</i> , 2015, 10, e0141330.	1.1	16
648	Nanomedicines in the treatment of acromegaly: focus on pegvisomant. <i>International Journal of Nanomedicine</i> , 2006, 1, 385-398.	3.3	21
649	Nanomedicines in the treatment of patients with hepatitis C co-infected with HIV ? focus on pegylated interferon-alpha. <i>International Journal of Nanomedicine</i> , 2006, 1, 399-409.	3.3	3
650	Does Pharmacodynamics of Drugs Change After Presenting them as Nanoparticles Like their Pharmacokinetics?. <i>Current Drug Targets</i> , 2020, 21, 807-818.	1.0	4
651	Polyethylene Glycol Acts as a Mechanistic Stabilizer of L-asparaginase: A Computational Probing. <i>Medicinal Chemistry</i> , 2019, 15, 705-714.	0.7	3
652	Targeted Strategies for Henipavirus Therapeutics. <i>The Open Virology Journal</i> , 2007, 1, 14-25.	1.8	16
653	Radiolabelled RGD peptides and peptidomimetics for tumour targeting. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 872.	3.0	73
654	Effects of a 24-week course of interferon- β therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2007, 13, 5343.	1.4	40
655	Personalized Approach in Nanomedicine. <i>Advances in Medical Technologies and Clinical Practice Book Series</i> , 0, , 1-21.	0.3	1
656	In vivo General Trends, Filtration and Toxicity of Nanoparticles. <i>Journal of Nanomaterials & Molecular Nanotechnology</i> , 2015, 02, .	0.1	2
657	PET Imaging of Integrin $\alpha_3\beta_1$ Expression. <i>Theranostics</i> , 2011, 1, 48-57.	4.6	117
658	Nanotechnology Based Approaches in Phage Therapy: Overcoming the Pharmacological Barriers. <i>Frontiers in Pharmacology</i> , 2021, 12, 699054.	1.6	25
659	Pegylierte Alpha-Interferone. <i>Pharma-Kritik (discontinued)</i> , 2002, 23, .	0.0	0

#	ARTICLE	IF	CITATIONS
660	Absorbable Delivery Systems for Cancer Therapy. Advances in Polymeric Biomaterials Series, 2003, , .	0.0	0
661	Therapeutic Nanodevices. , 2004, , 279-322.		1
662	Pharmacokinetics of Biologicals. , 2004, , 499-522.		0
663	Characterization of Biopharmaceutical Drugs. , 2006, , 329-390.		0
665	Therapeutic Nanodevices. , 2007, , 461-504.		1
666	Structural basis for the signal transduction of erythropoietin. , 2009, , 143-153.		0
668	Preparation and Evaluation of a 4-Branched Polyethylene Glycol Derivative Modified with Exendin-4 and Stearylamine for Extended Hypoglycemic Action. Journal of Pharmaceutical Investigation, 2010, 40, 175-180.	2.7	0
669	Development of functional cytokine mutants bymolecular evolution and drug delivery technology. Drug Delivery System, 2011, 26, 604-610.	0.0	0
670	Adverse Drug Effects and Pegylation. Southern Medical Journal, 2011, 104, 83-84.	0.3	0
671	Biologic Treatment of Crohnâ€™s Disease: Certolizumab. , 2012, , 407-412.		0
673	Surface Engineering of Biomembranes with GPI-Anchored Proteins and its Applications. , 2012, , 83-97.		0
674	Comparison of adefovir dipivoxil and pegylated interferon alpha-2a treatment in chronic hepatitis B patients. Åstanbul Kuzey Klinikleri, 2014, 1, 26-32.	0.1	0
675	A REVIEW ON CURRENT ADVANCES IN NANOTECHNOLOGY APPROACHES FOR THE EFFECTIVE DELIVERY OF ANTI-CANCER DRUGS. Journal of Drug Delivery and Therapeutics, 2014, .	0.2	2
677	Cancer Therapy: Absorbable Delivery Systems. , 0, , 1225-1239.		0
678	Carbohydrate Polymers: Colon-Targeted Drug Delivery. , 0, , 1285-1318.		0
679	Micelles: Polymeric and Lipid-Core Drug Delivery Systems. , 0, , 4574-4587.		0
680	Peptideâ€™Polymer Conjugates: Synthetic Design Strategies. , 0, , 5892-5906.		0
681	Immunotherapy and Vaccines. , 2016, , 441-464.		0

#	ARTICLE	IF	CITATIONS
682	Chapter 1: Nanotechnology Platforms and Physiological Challenges for Cancer Therapeutics. , 2017, , 1-20.		0
683	Peptideâ€“Polymer Conjugates: Synthetic Design Strategies. , 2017, , 1289-1303.		0
684	Personalized Approach in Nanomedicine. , 2018, , 1128-1148.		0
685	Electrophysiological effects of polyethylene glycol modified gold nanoparticles on mouse hippocampal neurons. Heliyon, 2020, 6, e05824.	1.4	6
686	Biotherapeutics ADME and PK/PD Principles. , 2022, , 77-100.		0
689	Pegylated interferon alpha-2a (40 kDa) in the treatment of chronic hepatitis B. International Journal of Nanomedicine, 2006, 1, 255-62.	3.3	8
691	Preclinical molecular imaging of tumor angiogenesis. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2010, 54, 291-308.	0.4	29
693	Type of pegylated interferon matters: another milestone in the treatment of hepatitis C virus infection. Hepatitis Monthly, 2010, 10, 165-7.	0.1	2
696	A comparative pharmacokinetic and pharmacodynamic study of two novel Cuban PEGylated rHuEPO MIRCERA and iorEPOCIM. Journal of Pharmacy and Pharmacognosy Research, 2018, 6, 179-190.	0.4	0
697	A Narrative Review of a Pulmonary Aerosolized Formulation or a Nasal Drop Using Sera Containing Neutralizing Antibodies Collected from COVID-19-Recovered Patients as a Probable Therapy for COVID-19. Iranian Journal of Medical Sciences, 2021, 46, 151-168.	0.3	2
698	Near-infrared spectroscopy: An important noninvasive and sensitive tool for point-of-care biosensing application. , 2022, , 161-184.		0
699	Nanotechnology: An Emerging Field in Protein Aggregation and Cancer Therapeutics. , 2022, , 177-207.		0
700	Human umbilical cord mesenchymal stem cell-derived exosomes carrying hsa-miRNA-128-3p suppress pancreatic ductal cell carcinoma by inhibiting Galectin-3. Clinical and Translational Oncology, 2022, 24, 517-531.	1.2	14
701	The Use of Uniform PEG Compounds in the Design of ADCs. RSC Drug Discovery Series, 2021, , 286-376.	0.2	2
702	Evasion of the accelerated blood clearance phenomenon by branched PEG lipid derivative coating of nanoemulsions. International Journal of Pharmaceutics, 2022, 612, 121365.	2.6	7
703	Developmental toxicity of nanomaterials used in drug delivery: understanding molecular biomechanics and potential remedial measures. , 2022, , 685-725.		4
704	Topology-Dependent Interaction of Cyclic Poly(ethylene glycol) Complexed with Gold Nanoparticles against Bovine Serum Albumin for a Colorimetric Change. Langmuir, 2021, , .	1.6	2
705	Localization of Multi-Lamellar Vesicle Nanoparticles to Injured Brain Tissue in a Controlled Cortical Impact Injury Model of Traumatic Brain Injury in Rodents. Neurotrauma Reports, 2022, 3, 158-167.	0.5	4

#	ARTICLE	IF	CITATIONS
706	Water-Soluble Luminescent Silicon Nanocrystals by Plasma-Induced Acrylic Acid Grafting and PEGylation. <i>ACS Applied Bio Materials</i> , 2022, 5, 105-112.	2.3	5
708	Engineering of the Recombinant Expression and PEGylation Efficiency of the Therapeutic Enzyme Human Thymidine Phosphorylase. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 793985.	2.0	1
713	Non-pegylated and Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma and the Risk of Severe Ocular Side-effects. <i>Acta Dermato-Venereologica</i> , 2022, 102, adv00722.	0.6	2
714	Metal-Phenolic Networks as Versatile Coating Materials for Biomedical Applications. <i>ACS Applied Bio Materials</i> , 2022, 5, 4687-4695.	2.3	18
715	Viral Dynamics and Pharmacokinetics of Peginterferon Alpha-2A and Peginterferon Alpha-2B in Naive Patients with Chronic Hepatitis C: A Randomized, Controlled Study. <i>Antiviral Therapy</i> , 2004, 9, 491-497.	0.6	82
716	Bioimaging guided pharmaceutical evaluations of nanomedicines for clinical translations. <i>Journal of Nanobiotechnology</i> , 2022, 20, 236.	4.2	9
717	Lipid nanoparticle steric stabilization roadmap. <i>Advances in Biomembranes and Lipid Self-Assembly</i> , 2022, , 41-75.	0.3	2
718	Chemical Conjugation in Drug Delivery Systems. <i>Frontiers in Chemistry</i> , 2022, 10, .	1.8	12
722	Nanocarriers: A boon to the drug delivery systems. , 2022, , 555-584.		0
723	Metal and metal oxide-based antiviral nanoparticles: Properties, mechanisms of action, and applications. <i>Advances in Colloid and Interface Science</i> , 2022, 306, 102726.	7.0	44
724	Pegvisomant: uso clnico en pacientes con acromegalia. <i>Revista Colombiana De Endocrinologa, Diabetes & Metabolismo</i> , 2022, 9, .	0.1	0
725	Porous Silicon Nanoparticles Targeted to the Extracellular Matrix for Therapeutic Protein Delivery in Traumatic Brain Injury. <i>Bioconjugate Chemistry</i> , 0, , .	1.8	7
726	Derivatization with fatty acids in peptide and protein drug discovery. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 59-80.	21.5	19
727	Future perspectives on peptide therapeutics. , 2022, , 699-726.		0
728	Thermosensitive liposomes for targeted breast cancer therapy. , 2022, , 351-368.		0
729	Immunostimulant plant proteins: Potential candidates as vaccine adjuvants. <i>Phytotherapy Research</i> , 2022, 36, 4345-4360.	2.8	2
730	Achievements and Bottlenecks of PEGylation in Nano-delivery Systems. <i>Current Medicinal Chemistry</i> , 2023, 30, 1386-1405.	1.2	4
731	Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	5

#	ARTICLE	IF	CITATIONS
732	A High-Affinity ⁶⁴ Cu-Labeled Ligand for PET Imaging of Hepsin: Design, Synthesis, and Characterization. <i>Pharmaceuticals</i> , 2022, 15, 1109.	1.7	0
733	Bioencapsulation of proteins in therapeutics. , 2022, , 155-178.		0
734	Design of pH-responsive polymeric nanocarrier for targeted delivery of pyrogallol with enhanced antitumor potential in colon cancer. <i>Archives of Biochemistry and Biophysics</i> , 2022, 731, 109431.	1.4	4
735	Liposome-assisted delivery of enzymes and proteins. , 2023, , 87-111.		1
736	Anti-platelet peptides targeting β_3 outside-in signaling pathway. <i>Current Protein and Peptide Science</i> , 2022, 24, .	0.7	0
737	Exposure of the Basophilic Cell Line KU812 to Liposomes Reveals Activation Profiles Associated with Potential Anaphylactic Responses Linked to Physico-Chemical Characteristics. <i>Pharmaceutics</i> , 2022, 14, 2470.	2.0	4
739	Hexapeptide decorated β -cyclodextrin delivery system for targeted therapy of bone infection. <i>Journal of Controlled Release</i> , 2023, 353, 337-349.	4.8	5
740	Direct Assessment of Oligomerization of Chemically Modified Peptides and Proteins in Formulations using DLS and DOSY-NMR. <i>Pharmaceutical Research</i> , 0, , .	1.7	5
741	Investigation of anti-PEG antibody response to PEG-containing cosmetic products in mice. <i>Journal of Controlled Release</i> , 2023, 354, 260-267.	4.8	11
742	Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture. <i>Journal of Controlled Release</i> , 2023, 354, 354-367.	4.8	5
743	Pegylation " in search of balance and enhanced bioavailability. <i>Journal of Medical Science</i> , 2022, 91, e761.	0.2	1
744	Theranostic applications of nanoemulsions in pulmonary diseases. , 2023, , 177-216.		0
746	Differences in protein distribution, conformation, and dynamics in hard and soft coronas: dependence on protein and particle electrostatics. <i>Physical Chemistry Chemical Physics</i> , 2023, 25, 7496-7507.	1.3	1
747	Virus-like particle-based nanocarriers as an emerging platform for drug delivery. <i>Journal of Drug Targeting</i> , 2023, 31, 433-455.	2.1	4
748	PEGylation, the Glorious Past, Present Dilemma and Future. , 0, 40, 338-344.		0
749	Dual-Responsive Enzyme"Polysaccharide Conjugate as a Nanocarrier System for Enzyme Prodrug Therapy. <i>Biomacromolecules</i> , 2023, 24, 2138-2148.	2.6	4
752	Drug delivery and functional nanoparticles. , 2023, , 447-484.		0
756	Poly(ethylene glycol) based biomaterials. , 2023, , 219-242.		0

#	ARTICLE	IF	CITATIONS
757	Nanoparticles for Targeted Drug Delivery Systems with Cancer Therapy in Perspective. , 2023, , 313-334.		0
758	Modeling and Simulation of Bio-Inspired Nanorobotic Drug Delivery System. Lecture Notes of the Institute for Computer Sciences, Social-Informatics and Telecommunications Engineering, 2023, , 64-76.	0.2	0
764	Biobetters: IFN- γ Variants with Reduced Immunogenicity for the Treatment of Human Viral Diseases. Infectious Diseases, 0, , .	4.0	0
767	Structure and modification. , 2024, , 297-394.		0
770	Emerging need of delivery systems for plant metabolites. , 2024, , 23-32.		0
771	Multifunctional nanocarrier-mediated approaches and conventional therapies for effective treatment of cancer. , 2024, , 35-61.		0